[go: up one dir, main page]

CA2925190A1 - Protecting group comprising a purification tag - Google Patents

Protecting group comprising a purification tag Download PDF

Info

Publication number
CA2925190A1
CA2925190A1 CA2925190A CA2925190A CA2925190A1 CA 2925190 A1 CA2925190 A1 CA 2925190A1 CA 2925190 A CA2925190 A CA 2925190A CA 2925190 A CA2925190 A CA 2925190A CA 2925190 A1 CA2925190 A1 CA 2925190A1
Authority
CA
Canada
Prior art keywords
formula
group
moiety
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2925190A
Other languages
French (fr)
Other versions
CA2925190C (en
Inventor
Harald Rau
Nicola BISEK
Thomas KNAPPE
Romy REIMANN
Sebastian Stark
Samuel WEISBROD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ascendis Pharma AS
Original Assignee
Ascendis Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma AS filed Critical Ascendis Pharma AS
Publication of CA2925190A1 publication Critical patent/CA2925190A1/en
Application granted granted Critical
Publication of CA2925190C publication Critical patent/CA2925190C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to compounds comprising a protecting group moiety-tag moiety conjugate, a method of purification and monoconjugates obtained from such method of purification.

Description

Protecting Group Comprising a Purification Tag Coupling reactions using two reagents, in which at least one is multi-functional, i.e. has more than one functional group for reaction with the other reagent, usually leads to a distribution of mono-, di-, tri- and higher conjugates, depending on the number of functional groups available. The isolation of conjugates of a specific type, for example the monomer, can be difficult or impossible, especially when the relative molecular weight difference between the different types of conjugates is small.
Accordingly, there is a need for reagents and methods that at least partially overcome the above described shortcomings.
It is therefore an object of the present invention to at least partially overcome the above-described shortcomings by providing compounds comprising protecting groups with a tag moiety that can be conjugated to high molecular weight entities, such as proteins, which allow the isolation of mono-, di- and higher conjugates.
In one aspect the present invention relates to a compound comprising a moiety of formula (I) T ¨ PG -Ir (I), wherein the dashed line indicates attachment to the rest of the compound;
T is a tag moiety; and PG is a protecting group moiety.
It was now surprisingly found that the use of this protecting group comprising a tag moiety allows the isolation of, for example, monoconjugates from a mixture of mono-, di-, tri- and higher conjugates. As the tag moiety is conjugated to a protecting group, it is removed upon removal of the protecting group and is thus not present in the compound in which such tag moiety-protecting group conjugate was used.
Within the present invention the terms are used with the meaning as follows.
2 As used herein, the term "functional group" means a group of atoms which can react with other functional groups. Functional groups include but are not limited to the following groups:
carboxylic acid (¨(C=0)0H), primary or secondary amine (¨NH2, ¨NH¨), maleimide, thiol (-SH), sulfonic acid (¨(0=S=0)0H), carbonate, carbamate (-0(C=0)N<), hydroxyl (¨OH), aldehyde (¨(C=0)H), ketone (¨(C=0)¨), hydrazine (>N-N<), isocyanate, isothiocyanate, phosphoric acid (-0(P=0)0HOH), phosphonic acid (-0(P=0)0HH), haloacetyl, alkyl halide, acryloyl, aryl fluoride, hydroxylamine, disulfide, vinyl sulfone, vinyl ketone, diazoalkane, oxirane, and aziridine.
If a functional group reacts with another functional group, the resulting chemical structure is referred to as "linkage". For example, the reaction of an amine functional with a carboxyl functional group results in an amide linkage.
As used herein, the term "reagent" means a chemical compound which comprises at least one functional group for reaction with the functional group of another reagent or moiety.
As used herein, the term "moiety" means a part of a molecule, which lacks one or more atom(s) compared to the corresponding reagent. If, for example, a reagent of the formula "H-X-H" reacts with another reagent and becomes part of the reaction product, the corresponding moiety of the reaction product has the structure "H¨X¨" or "¨X¨ " , whereas each "¨ "
indicates attachment to another moiety.
Accordingly, the phrase "in bound form" is used to refer to the corresponding moiety of a reagent, i.e. "lysine in bound form" refers to a lysine moiety which lacks one or more atom(s) of the lysine reagent and is part of a molecule.
As used herein, the term "reversible prodrug linker moiety" means a moiety which on its one end is attached to another moiety, preferably a biologically active moiety, through a reversible linkage and on another end is attached through a permanent or reversible linkage to another moiety. A "reversible linkage" is a linkage that is non-enzymatically hydrolytically degradable, i.e. cleavable, under physiological conditions (aqueous buffer at pH 7.4, 37 C) with a half-life ranging from one hour to twelve months. In contrast, a "permanent linkage" is non-enzymatically hydrolytically degradable under physiological conditions (aqueous buffer at pH 7.4, 37 C) with half-lives of more than twelve months.
3 Such reversible prodrug linker moieties are used in prodrugs. Prodrugs are compounds that undergo biotransformation before exhibiting their pharmacological effects.
Prodrugs can thus be viewed as biologically active moieties connected to specialized non-toxic protective groups used in a transient manner to alter or to eliminate undesirable properties in the parent molecule. This also includes the enhancement of desirable properties in the drug and the suppression of undesirable properties. The biologically active moiety is connected to the protective group through a reversible prodrug linker.
As used herein, the term "polymer" means a molecule comprising repeating structural units, i.e. monomers, connected by chemical bonds in a linear, circular, branched, crosslinked or dendrimeric way or a combination thereof, which may be of synthetic or biological origin or a combination of both. It is understood that a polymer may for example also comprise functional groups. A polymer is referred to as a "homopolymer" if the polymer is composed of the same monomers and is referred to as a "copolymer" if the polymer is composed of different monomers.
As used herein, the term "polymeric" means a reagent or a moiety comprising one or more polymer(s).
As used herein, the term "PEG-based" refers to a moiety comprising at least 10%
poly(ethylene glycol) (PEG), e.g. at least 15% PEG, at least 20% PEG, at least 25% PEG, at least 30% PEG.
As used herein, the term "tag moiety" refers to a moiety which when conjugated to a second moiety confers (a) physical and/or chemical property/properties not present in said second moiety without the tag moiety and which different physical and/or chemical property/properties allow the purification of such a conjugate.
As used herein, the term "protecting group moiety" refers to a moiety that is used for the reversible protection of functional groups during chemical reaction processes to render these functional groups unreactive in said chemical reaction processes.
As used herein, the term "spacer moiety" refers to any moiety suitable for connecting two moieties. Preferably, the term "spacer moiety" refers to a chemical bond, C1_50 alkyl, C2_50
4 alkenyl or C2_50 alkynyl, which C1_50 alkyl, C2_50 alkenyl or C2_50 alkynyl is optionally interrupted by one or more groups selected from Q, -C(0)0-; -0-; -C(0)-; -C(0)N(R11)-;
-S(0)2N(R11)-; -S(0)N(R11)-; -S(0)2-; -S(0)-; -N(R11)S(0)2N(Rila)-; -S-; -N(R11)-;
-0C(0)R11; -N(R11)C(0)-;
-N(Ri 1)S(0)2-; -N(R11)S(0)-; -N(R11)C(0)0-;
-N(R11)C(0)N(R1 1 a; and -0C(0)N(R11R1 la) N _ A which ci and =_A_50 alkyl, C2_50 alkenyl Or C2-50 alkynyl is optionally substituted by one or more substituents as defined below;
wherein Q is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl;
tetralinyl;
C3_10 cycloalkyl; 4- to 7-membered heterocyclyl; or 8- to 11- membered heterobicyclyl, wherein Q is optionally substituted with one or more Rm, which are the same or different; and R105 RH and R 1 la areindependently selected from the group consisting of H;
and C1-6 alkyl, wherein C1_6 alkyl is optionally substituted with one or more halogen, which are the same or different.
As used herein, the term "C1_4 alkyl" alone or in combination means a straight-chain or branched alkyl group having 1 to 4 carbon atoms. If present at the end of a molecule, examples of straight-chain and branched Ci _4 alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl. When two moieties of a molecule are linked by the C1_4 alkyl group, then examples for such Ci_4 alkyl groups are --CH2-CH2-, -CH(CH3)-, -CH2-CH2-CH2-, -CH(C2H5)-, -C(CH3)2-, -CH2-CH2-CH2-CH2-, and -CH2-CH2-CH2(CH3)-. Each hydrogen atom of a Ci_4 alkyl group may be replaced by a substituent as defined below.
As used herein, the term "C1_6 alkyl" alone or in combination means a straight-chain or branched alkyl group having 1 to 6 carbon atoms. If present at the end of a molecule, examples of straight-chain and branched Ci _6 alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl and 3,3 -dimethylpropyl. When two moieties of a molecule are linked by the C1_6 alkyl group, then examples for such Ci _6 alkyl groups are -CH2-, -CH2-CH2-, -CH(CH3)-, -CH2-CH2-CH(C2H5)- and -C(CH3)2-. Each hydrogen atom of a Ci_6 alkyl group may optionally be replaced by a substituent as defined below.
5 As used herein, the term "C1_50 alkyl" alone or in combination means a straight-chain or branched alkyl group having 1 to 50 carbon atoms. Each hydrogen atom of a Co alkyl group may optionally be replaced by a substituent. In each case the alkyl group may be present at the end of a molecule or two moieties of a molecule may be linked by the alkyl group.

The term "C2_50 alkenyl" alone or in combination means a straight-chain or branched hydrocarbon residue comprising at least one carbon-carbon double bond having 2 to 50 carbon atoms. If present at the end of a molecule, examples are -CH=CH2, -CH=CH-CH3, -CH2-CH=CH2, -CH=CHCH2-CH3 and -CH=CH-CH=CH2. When two moieties of a molecule are linked by the alkenyl group, then an example is e.g. -CH=CH-. Each hydrogen atom of a C2_50 alkenyl group may optionally be replaced by a substituent as defined below.
As used herein, the term "C2_50 alkynyl" alone or in combination means a straight-chain or branched hydrocarbon residue comprising at least one carbon-carbon triple bond having 2 to 50 carbon atoms. If present at the end of a molecule, examples are -CCH, -CH2-CCH, CH2-CH2-CCH and CH2-CC-CH3. When two moieties of a molecule are linked by the alkynyl group, then an example is -CC-. Each hydrogen atom of a C2_50 alkynyl group may optionally be replaced by a substituent as defined below. Optionally, one or more double bond(s) may occur.
As used herein, the term "C3_10 cycloalkyl" means a carbocyclic ring system having 3 to 10 carbon atoms, which may be saturated or unsaturated, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl. The term "C3_10 cycloalkyl" also includes at least partially saturated carbomono-and ¨bicycles.
Each hydrogen atom of a C3_10 cycloalkyl may optionally be replaced by a substituent as defined below.
As used herein, the term "4- to 7-membered heterocycly1" or "4- to 7-membered heterocycle"
means a ring with 4, 5, 6 or 7 ring atoms that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated) wherein at least one ring atom up to 4 ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including -S(0)-, -S(0)2-), oxygen and nitrogen (including =N(0)-) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom. Examples for 4- to 7-membered heterocycles include but are not limited to azetidine, oxetane, thietane,
6 furan, thiophene, pyrrole, pyrroline, imidazole, imidazoline, pyrazole, pyrazoline, oxazole, oxazoline, isoxazo le, isoxazoline, thiazo le, thiazoline, isothiazo le, isothiazo line, thiadiazo le, thiadiazo line, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazo lidine, sulfo lane, pyran, dihydropyran, tetrahydropyran, imidazolidine, pyridine, pyridazine, pyrazine, pyrimidine, piperazine, piperidine, morpho line, tetrazole, triazole, triazolidine, tetrazolidine, diazepane, azepine and homopiperazine. Each hydrogen atom of a 4- to 7-membered heterocyclyl or 4- to
7-membered heterocycle may optionally be replaced by a substituent as defined below.
As used herein, the term "8- to 11-membered heterobicycly1" or "8- to 11-membered heterobicycle" means a heterocyclic system of two rings with 8 to 11 ring atoms, where at least one ring atom is shared by both rings and that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated) wherein at least one ring atom up to 6 ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including -S(0)-, -S(0)2-), oxygen and nitrogen (including =N(0)-) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom. Examples for a 8- to 11-membered heterobicycle are indole, indoline, benzofuran, benzothiophene, benzoxazo le, benzisoxazo le, benzothiazo le, benzisothiazo le, benzimidazo le, benzimidazo line, quino line, quinazo line, dihydroquinazo line, quino line, dihydroquino line, tetrahydroquino line, decahydroquino line, isoquino line, decahydroisoquino line, tetrahydroisoquinoline, dihydroisoquinoline, benzazepine, purine and pteridine. The term 8-to 11-membered heterobicycle also includes spiro structures of two rings like 1,4-dioxa-8-azaspiro[4.5]decane or bridged heterocycles like 8-aza-bicyclo[3.2.1]octane.
Each hydrogen atom of an 8- to 11-membered heterobicyclyl or 8- to 11-membered heterobicycle carbon may be replaced by a substituent as defined below.
As used herein, the term "aromatic" refers to a cyclic or polycyclic moiety wherein the number of pi electrons must satisfy the Hiickel rule (4n+2) and the cycle or polycycle is planar.
As used herein, the term "water-soluble" refers to a compound of which at least 1 g of said compound can be dissolved in one liter of water at 20 C to form a homogeneous solution. The term "water-insoluble" refers to a compound of which less than 1 g of said compound can be dissolved in one liter of water at 20 C to form a homogeneous solution.

As used herein, the term "halogen" means fluoro, chloro, bromo or iodo.
Particulary preferred is fluoro or chloro.
As used herein, the term "substituted" means that one or more ¨H atom(s) of a moiety, compound or conjugate are replaced by a different atom or a group of atoms, which are referred to as "substituent". Suitable substituents are selected from the group consisting of halogen; -CN; -COOR9; -0R9; -C(0)R9; -C(0)N(R9R9a); -S(0)2N(R9R9a); -S(0)N(R9R9a);
-S(0)2R9; -S(0)R9; -N(R9)S(0)2N(R9aR9b); -SR9; -N(R9R9a); -NO2; -0C(0)R9;
-N(R9)C(0)R9a; -N(R9)S(0)2R9a; -N(R9)S(0)R9a; -N(R9)C(0)0R9a; -N(R9)C(0)N(R9aR9b);
-0C(0)N(R9R9a); Q; C 1 _50 alkyl; C2_50 alkenyl; and C2_50 alkynyl, wherein Q;
C 1 _50 alkyl; C2-50 alkenyl; and C2_50 alkynyl are optionally substituted with one or more R1 , which are the same or different and wherein C1_50 alkyl; C2_50 alkenyl; and Co alkynyl are optionally interrupted by one or more group(s) selected from the group consisting of Q, -C(0)0-; -0-;
-C(0)-;
-C(0)N(R11)-; -S(0)2N(R11)-; -S(0)N(R11)-; -S(0)2-; -5(0)-; _N(R)s(o)2N(R)_; -S-;
-N(R11)-; -0C(0)R11; -N(R11)C(0)-; -N(R11)S(0)2-; -N(R11)S(0)-; -N(R11)C(0)0-;
-N(R11)C(0)N(R1 lit). and -0C(0)N(R11R1 la);
wherein R9, R9a, R9b are independently selected from the group consisting of H; Q;
C 1_50 alkyl; C2_50 alkenyl; and C2_50 alkynyl, wherein Q; C1-50 alkyl; C2_50 alkenyl; and C2_50 alkynyl are optionally substituted with one or more R1 , which are the same or different and wherein C1_50 alkyl; C2_50 alkenyl; and C2_50 alkynyl are optionally interrupted by one or more group(s) selected from the group consisting of Q, -C(0)0-; -0-; -C(0)-; -C(0)N(R11)-; -S(0)2N(R11)-; -S(0)N(R11)-; -S(0)2-;
- 5 (0)-;
-N(R11)S(0)2N(Rila)-; -S-; -N(R11)-; -0C(0)R11; -N(R11)C(0)-; -N(R11)S(0)2-; -N(R11)S(0)-;
-N(R11)C(0)0-;
-N(R11)C(0)N(R11a)-; and -0C(0)N(R11R1 la);
Q is selected from the group consisting of phenyl; naphthyl;
indenyl; indanyl; tetralinyl; C3_10 cycloalkyl; 4- to 7-membered heterocyclyl; or 8- to 11- membered heterobicyclyl, wherein Q
is optionally substituted with one or more R1 , which are the same or different;
8 Rio is halogen; -CN; oxo (=0); -COOR12; -0R12; -C(0)R12;
-C(0)N(R12R12a);
-S(0)2N(R12R12a);
-S(0)N(R12R12a);
-S(0)2R12; _s(0)R12; _N(R12) S(0)2N(R12aR12); _SR12;
-N(Ri2Ri2a);
-NO2; -0C(0)R12;
-N(R12)C(0)R12a;
-N(R12)S(0)2R12a; -N(R12)S(0)R12a; N(R12)c(0)OR'2a ; _ ) -N(R12)C(0)N(R12aRl2b.) OC(0)N(R12R12a.;
or C1-6 alkyl, wherein C1_6 alkyl is optionally substituted with one or more halogen, which are the same or different;
RH, Rlla 5 R'2, R12a5 R12b are independently selected from the group consisting of H; or C1_6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different.
In one embodiment R9, R9a, R9b may be independently of each other H.
In one embodiment R1 is C1_6 alkyl.
In one embodiment T is phenyl.
Preferably, a maximum of 6 ¨H atoms of a moiety are independently replaced by a substituent, e.g. 5 ¨H atoms are independently replaced by a substiuent, 4 ¨H
atoms are independently replaced by a substituent, 3 ¨H atoms are independently replaced by a substituent, 2 ¨H atoms are independently replaced by a substituent, or 1 ¨H
atom is replaced by a substituent.
As used herein, the term "peptide" refers to a chain of two to fifty amino acid monomers linked by peptide bonds. As used herein, the term "protein" refers to a chain of more than fifty amino acid monomers linked by peptide bonds. Preferably, a protein comprises less than 10000 amino acids monomers, such as no more than 5000 amino acid monomers or no more than 2000 amino acid monomers.
As used herein, the term "polyamine" refers to a moiety having at least 3 amine functional groups and preferably at most 20 amine functional groups. Even more preferably, such polyamine has 3, 4, 5, 6, 7, 8, 9 or 10 amine functional groups.
9 In general the term "comprise" or "comprising" also encompasses "consist of' or "consisting o f '.
In the following paragraphs the invention is described in further detail.
In one embodiment, T of formula (I) comprises a polymeric moiety. Preferably, T of formula (I) comprises a polymer selected from the group consisting of 2-methacryloyl-oxyethyl phosphoyl cholins, poly(acrylic acids), poly(acrylates), poly(acrylamides), poly(alkyloxy) polymers, poly(amides), poly(amidoamines), poly(amino acids), poly(anhydrides), poly(aspartamides), poly(butyric acids), poly(glycolic acids), polybutylene terephthalates, poly(caprolactones), poly(carbonates), poly(cyanoacrylates), poly(dimethylacrylamides), poly(esters), poly(ethylenes), poly(alkylene glycols), poly(ethylene oxides), poly(ethyl phosphates), poly(ethyloxazolines), poly(glycolic acids), poly(hydroxyethyl acrylates), poly(hydroxyethyl-oxazo lines), poly(hydroxymethacrylates), poly(hydroxypropylmethacrylamides), poly(hydroxypropyl methacrylates), poly(hydroxypropyloxazolines), poly(imino carbonates), poly(lactic acids), poly(lactic-co-glycolic acids), poly(methacrylamides), poly(methacrylates), poly(methyloxazolines), poly(organophosphazenes), poly(ortho esters), poly(oxazolines), poly(propylene glycols), poly(silo xanes), poly(urethanes), poly(vinyl alcohols), poly(vinyl amines), poly(vinylmethylethers), poly(vinylpyrrolidones), silicones, celluloses, carbomethyl celluloses, hydroxypropyl methylcelluloses, chitins, chitosans, dextrans, dextrins, gelatins, hyaluronic acids and derivatives, functionalized hyaluronic acids, mannans, pectins, rhamnogalacturonans, starches, hydroxyalkyl starches, hydroxyethyl starches and other carbohydrate-based polymers, xylans, and copolymers thereof.
If T of formula (I) is a polymeric moiety it is preferred that T has a molecular weight of at least 1 kDa, preferably of at least 3 kDa and most preferably of at least 5 kDa. If T of formula (I) is a polymeric moiety it is preferred that it has a molecular weight of at most 1000 kDa, e.g. at most 800 kDa, at most 500 kDa, at most 250 kDa, at most 200 kDa, or at most 100 kDa.
In another embodiment, T of formula (I) comprises an affinity ligand.
Preferably, T of formula (I) comprises, more preferably T is an affinity ligand moiety selected from the group consisting of 4-aminobenzamidine, 3-(2'-aminobenzhydryloxy)tropane, 8-aminocaproyl-p-chlorobenzylamide, 1 -amino -4- [3 -(4 ,6-dichlorotriazin-2-ylamino)-4-sulfophenylamino]anthraquinone-2-sulfonic acid, 2-(2'-amino-4'-methylphenylthio)-N,N-dimethylbenzylamine dihydrochloride, angiopoietin-1, aptamers, arotinoid acid, avidin, biotin, calmodulin, cocaethylene, cytosporone B, N,N-dihexy1-2-(4-fluorophenyl)indole-3-acetamide, N,N-dipropy1-2-(4-chloropheny1)-6,8-dichloro-imidazo [1,2-a]
pyridine-3 -acetamide, 5-fluoro-2'-deoxyuridine 5'-(p-aminophenyl) monophosphate, S-hexyl-L-g lutathione, (S,S)-4-phenyl-a-(4-phenylo xazo lidin-2-ylidene)-2-oxazo line-2-acetonitrile, Pro -Leu-Gly hydroxamate, 2-(4-(2-(trifluoromethyl)phenyl)piperidine-1-carboxamido)benzoic acid, trimethyl(m-aminophenyl)ammonium chloride, urocortin III, cofactors like adenosin
10 triphosphate, s-adenosyl methionine, ascorbic acid, cobalamine, coenzyme A, coenzyme B, coenzyme M, coenzyme Q, coenzyme F420, cytidine triphosphate, flavin mononucleotide, flavin adenine dinucleotide, glutathion, heme, lipoamide, menaquinone, methanofuran, methylcobalamine, molybdopterin, NAD+, NADP+, nucleotide sugars, 3'-phosphoadenosine-5 '-phosphosulfate, pyridoxal phosphate, polyhistidines, pyrroloquinoline quinone, riboflavin, streptavidin, tetrahydrobiopterin, tetrahydromethanopterin, tetrahydrofolic acid, biotin carboxyl carrier protein (BCCP), chitin binding protein, FK506 binding proteins, FLAG tag, green fluorescent protein, glutathion-S-transferase, hemagglutinin, maltose binding protein, myc tag, NusA, protein C epitope, S-tag, strep-tag, thioredoxins, triazines and antibody fragments.
If T of formula (I) comprises an affinity ligand, it is preferred that the affinity ligand is a polyhistidine.
In another embodiment, T of formula (I) comprises a charged moiety.
Preferably, T of formula (I) comprises at least one positive and/or negative charge in aqueous conditions. It is understood that the number of positive and negative charges of T is unequal to ensure that T
is a charged molecule.
Preferably, T of formula (I) comprises at least one positive or negative charge in aqueous conditions, e.g. at least two positive or negative charges, at least three positive or negative charges, at least four positive or negative charges, at least five positive or negative charges, at least six positive or negative charges, at least seven positive or negative charges, at least eight positive or negative charges, at least nine positive or negative charges, at least ten positive or negative charges, at least eleven positive or negative charges, at least twelve positive or
11 negative charges, at least thirteen positive or negative charges, at least fourteen positive or negative charges or at least fifteen positive or negative charges in aqueous conditions.
In one embodiment, T of formula (I) comprises at least one negative charge under aqueous conditions at pH 4 to 10, preferably at pH 6 to 10, such as one negative charge, two negative charges, three negative charges, four negative charges, five negative charges, six negative charges, seven negative charges, eight negative charges, nine negative charges, ten negative charges, eleven negative charges, twelve negative charges, thirteen negative charges, fourteen negative charges or fifteen negative charges under aqueous conditions at pH 4 to 10, preferably at pH 6 to 10. More preferably, T of formula (I) comprises one negative charge, two negative charges, three negative charges, four negative charges, five negative charges, six negative charges, seven negative charges or eight negative charges under aqueous conditions at pH 4 to 10, preferably at pH 6 to 10. More preferably, T of formula (I) comprises two negative charges, three negative charges, four negative charges, five negative charges or six negative charges under aqueous conditions at pH 4 to 10, preferably at pH 6 to 10.
More preferably, T of formula (I) comprises at least one positive charge under aqueous conditions at pH 3 to 9, preferably at pH 3 to 7, such as one positive charge, two positive charges, three positive charges, four positive charges, five positive charges, six positive charges, seven positive charges, eight positive charges, nine positive charges, ten positive charges, eleven positive charges, twelve positive charges, thirteen positive charges, fourteen positive charges or fifteen positive charges under aqueous conditions at pH 3 to 9, preferably at pH 3 to 7. More preferably, T of formula (I) comprises one positive charge, two positive charges, three positive charges, four positive charges, five positive charges, six positive charges, seven positive charges or eight positive charges under aqueous conditions at pH 3 to 9, preferably at pH 3 to 7. More preferably, T of formula (I) comprises two positive charges, three positive charges, four positive charges, five positive charges or six positive charges under aqueous conditions at pH 3 to 9, preferably at pH 3 to 7.
Preferably, the at least one positive charge of T of formula (I) is provided by an ammonium, phosphonium or tertiary amine. Preferably, the at least one positive charge of T of formula (I) is provided by an ammonium or phosphonium. In a specific embodiment, the at least one positive charge of T of formula (I) is provided by a tertiary amine.
12 Preferably, T of formula (I) comprises a polyamide comprising at least one tertiary amine, quaternary ammonium residue and/or at least one protonated ammonium residue, optionally comprising further functional groups. Preferably, such optional further functional groups are amine functional groups. Preferably, T of formula (I) comprises at least one tertiary amine or quaternary ammonium residue and/or at least one protonated ammonium residue.
Even more preferably, T of formula (I) comprises four quaternary ammonium residues and/or four protonated ammonium residues.
In another preferred embodiment, T of formula (I) comprises at least one tertiary amine, such as 1, 2, 3, 4, 5 or 6 tertiary amines, and optionally comprises further functional groups. More preferably, T of formula (I) comprises 3, 4 or 5 tertiary amines and most preferably, T of formula (I) comprises 4 tertiary amines.
Preferably, T of formula (I) comprises in bound form a polyamine. More preferably, T of formula (I) comprises in bound form a polyamine selected from the group consisting of ethylene diamine, 1,3- diaminopropane, hexamethylene diamine, cadaverin, putrescin, spermine, spermidine, norspermidine and tetraethylmethylenediamine.
Even more preferably, T of formula (I) comprises a moiety of formula (a):

p,R4a 0 Ri H H H
R4b R1 a N
- - x SP = H NRlb - - n x 3b N
R I
x +2RbR22a (a), wherein the dashed line indicates attachment to the rest of the compound, i.e. to PG
of formula (I);
R15 Ria5 R115 R25 R2a5 R2135 R3 R3a5 R3135 R45 R4a5 =-= 4b K
are independently of each other H
or methyl;
each m is independently of each other 1, 2, 3, 4, 5, 6, 7, or 8;
each n is independently of each other 1, 2, 3, 4, 5, 6, 7, or 8;
each x is independently of each other 1, 2, 3, 4, 5, 6, 7 or 8:
13 each y is independently of each other 0, 1, 2, 3, 4, 5, 6, 7 or 8; and SP is a spacer moiety.
Preferably, the moiety of formula (a) is symmetric, i.e. the moiety +0. R4a 1\1,b H 1\1"
- - x H
3 b R
L - x - -m R3a 13 R
is the same as the moiety - - 1 .-=R1 a N HNR1b H x - R2 , - - H
2a - n - -m x \ 2bR

In one embodiment Ri, Rla, Rib of formula (a) are all methyl.
In another embodiment Ri of formula (a) is H and Ria and Rib of formula (a) are both methyl.
In one embodiment R2, R2a5 R2b of formula (a) are all methyl.
In another embodiment R2 of formula (a) is H and R2a and R2b of formula (a) are both methyl.
In one embodiment R3, R3a, R3b of formula (a) are all methyl.
In another embodiment R3 of formula (a) is H and R3a and R3b of formula (a) are both methyl.
In one embodiment R4, R4a5b of formula (a) are all methyl.
14 In another embodiment R4 of formula (a) is H and R4a and R4b of formula (a) are both methyl.
Preferably, m of formula (a) is 1, 2, 3, 4, 5 or 6. More preferably, m of formula (a) is 2, 3, 4, or 5, even more preferably, m of formula (a) is 3, 4 or 5 and most preferably, m of formula (a) is 4.
Preferably, n of formula (a) is 1, 2, 3, 4, 5 or 6. More preferably, n of formula (a) is 2, 3, 4, or 5, even more preferably, n of formula (a) is 2, 3 or 4 and most preferably, n of formula (a) is 3.
Preferably, x of formula (a) is 1, 2, 3, 4, 5 or 6. More preferably, n of formula (a) is 1, 2, 3, or 4, even more preferably, x of formula (a) is 1, 2, or 3 and most preferably, x of formula (a) is 1.
Preferably, y of formula (a) is 1, 2, 3, 4, 5 or 6. More preferably, y of formula (a) is 1, 2, 3, or 4, even more preferably, y of formula (a) is 1, 2, or 3 and most preferably, y of formula (a) is 1.
In one preferred embodiment, R1, Rla, Rib, R2, R2a, R2b, R3, R3a, R3b, R4, R4a, R4bare methyl;
m is 4; n is 3; y is 1 and x is 1.
In another preferred embodiment, R15 R25 R3, R4 are H; Rla, Rib, R2a, R2b, R3a, R3b, R4a, R4b are methyl, m is 4; n is 3; y is 1 and xis 1.
Preferred counter ions for T of formula (I) are a, TFA- and SO4-.
In another preferred embodiment T of formula (I) comprises a moiety of formula (b):

[ se] NH

ONV
HNO
N/
N/
NH
NVrNrL
0 H N, 0 N/
wherein the dashed line indicates attachment to PG of formula (I);
q is 0 or 1; and 5 SP is a spacer moiety.
PG of formula (I) is a protecting group moiety. Suitable protecting group moieties are known in the art.
10 If PG of formula (I) is used for the reversible protection of a thiol functional group PG is preferably selected from the group consisting of * ' ' II ' , R 3-(i0 * II II * 04 I I
/AI -cy -1=
0 0 0 R ¨
, *
101 11 Me0 /fp ' *µ .
,and
15 wherein
16 the dashed line marked with an asterisk indicates attachment to T of formula (I) and the unmarked dashed line indicates attachment to the rest of the compound comprising the moiety of formula (I);
Ar is an aromatic moiety which is optionally further substituted; and le, R 3, R 4 are independently of each other a chemical bond or is C1_50 alkyl; C2-50 alkenyl; or C2_50 alkynyl, wherein C1_50 alkyl; C2_50 alkenyl; and C2-50 alkynyl are optionally substituted with one or more R3, which are the same or different and wherein C1_50 alkyl; C2_50 alkenyl; and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -Q-, -C(0)0-; -0-; -C(0)-; -C(0)N(R4)-;
-S(0)2N(R4)-; -S(0)N(R4)-; -S(0)2-; -S(0)-; -N(R4)S(0)2N(R4a)-; -S-;
-N(R4)-; -0C(0)R4; -N(R4)C(0)-; -N(R4)S(0)2-; -N(R4)S(0)-;
-N(R4)C(0)0-; -N(R4)C(0)N(R4a)-; and -0C(0)N(R4R4a);
R 2 is -H; C1_50 alkyl; C2_50 alkenyl; or C2_50 alkynyl, wherein C1_50 alkyl; C2-so alkenyl; and C2_50 alkynyl are optionally substituted with one or more R3, which are the same or different and wherein C1_50 alkyl; C2-50 alkenyl; and C2_50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -Q-, -C(0)0-; -0-; -C(0)-;
-C(0)N(R4)-; -S(0)2N(R4)-; -S(0)N(R4)-; -S(0)2-; -S(0)-;
-N(R4)S(0)2N(R4a)-; -S-; -N(R4)-; -0C(0)R4; -N(R4)C(0)-;
-N(R4)S(0)2-; -N(R4)S(0)-; -N(R4)C(0)0-; -N(R4)C(0)N(R4a)-; and -oc(o)N(R4R4a);
Q is selected from the group consisting of phenyl;
naphthyl; indenyl;
indanyl; tetralinyl; C3_10 cycloalkyl; 4- to 7-membered heterocyclyl; and 8- to 11- membered heterobicyclyl, wherein T is optionally substituted with one or more R3, which are the same or different;
R3 is halogen; -CN; oxo (=0); -COOR5; -0R5; -C(0)R5; -C(0)N(R5R5a);
-S(0)2N(R5R5a); -S(0)N(R5R5a); -S(0)2R5;
-N(R5)S(0)2N(R5aR5b); -SR5; -N(R5R5a); -NO2; -0C(0)R5;
-N(R5)C(0)R5a; -N(R5)S(0)2R5a; -N(R5)S(0)R5a; -N(R5)C(0)0R5a;
-N(R5)C(0)N(R5aR5b); -0C(0)N(R5R5a); or Ci_6 alkyl, wherein C1_6 alkyl is optionally substituted with one or more halogen, which are the same or different; and
17 R45 R4a5 R55b K R5 are independently selected from the group consisting of -H; or C1_6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different.
Preferably, R 1 is C1_6 alkyl. Even more preferably, R 1 is selected from -CH2-and -CH2-CH2-CH2-.
Preferably, R 2 is selected from H and Ci_6 alkyl.
Preferably, R 3 is Ci_6 alkyl.
Preferably, R 4 is Ci_6 alkyl.
Preferably, Ar is selected from the group consisting of I I I
)<N 5 5 *
I
5 5 )<1\r)\T 5 1\l''N 5 N N *
I = I I I
N,N 5 5 * =
- -5 =
*
*OW t W
p;7.1'1 µ5. r*

_ - - -
18 W,* W * W , r=
w. r and wherein dashed lines marked with an asterisk indicate attachment to T of formula (I) and the unmarked dashed lines indicate attachment to the rest of PG of formula (I);
W is independently of each other 0, S, or NR;
W' is N;
is H, Ci_4 alkyl; and wherein Ar is optionally substituted with one or more substituent(s) independently selected from the group consisting of NO2, Cl and F.
More preferably, PG of formula (I) is selected from the group consisting of *1 II *1 01 II I ,/-1Z03N
Iii I I
Ar -S 0 0 0 ' (05 (ii), (iii), (iv) and * 04 (iv), wherein the dashed line marked with an asterisk indicates attachment to T of formula (I) and the unmarked dashed line indicates attachment to the rest of the compound of formula (I); and Ar, R 1, R02, 03 and R 4 are used as above;
if PG of formula (I) is used for the reversible protection of a thiol functional group.
Preferred embodiments of Ar, R 1, R02, 03 and R 4 are as described above.
If PG of formula (I) is used for the reversible protection of a thiol functional group, PG is most preferably
19 ,)V ' , wherein the dashed line marked with an asterisk indicates attachment to T of formula (I) and the unmarked dashed line indicates attachment to the rest of the compound comprising the moiety of formula (I).
If PG of formula (I) is used for the reversible protection of an amine functional group, PG of formula (I) preferably comprises a moiety selected from the group consisting of , A , * 0 jC
)7....o o, o ,*
# .
Me0 [101*
s f76:rõ
, , . .

,0 * s , , , *
, ,{7a:61,0 ,, , H$
11 41' *N''N
* ,, F I 0 = ' I 0 0 , 0 =
s'e *
., H N ' 1 H N HIr .N.--N11(1), I\T
N '''I\TIN .N t 0 ,,, .,N N
I 0 = I 0 I 0 ' 0 0 , *
.
H1r H4 ' H
I\T
*' T
N N .N...........õN
*;,(.N.--..õ.., N -...
. I 0 ' I 0 , I
0 ' 0 = 0 = 0 , , , , .
N ' H N Hr21-N14*
, .N..........õN *,....1/4,õ N.......õ N ... N
I 0 ' I 0 ,' I 0 ' 0 = , 0 = 0 =
- - [-*-. I 0 ,' * = 0 N ' , 0 = i %` .
R0 I.
, and 0 * 0 * , A
, 0 , wherein the dashed line marked with the asterisk indicates attachment to T of formula (I) and the unmarked dashed line indicates attachment to the rest of the compound comprising the moiety of formula (I); and R is Ci_6 alkyl.

More preferably, if PG of formula (I) is used for the reversible protection of an amine functional group, PG of formula (I) preferably comprises a moiety selected from the group consisting of *, 0 *, ' AI 0- -.= :, 0 0 )Z
0)' *
_0 o o , *
. Me0 #
*
;µ, = 41 , * ' 0 , , , , *
0 , ' afr-, , Vi H$
*N''N
* - F 0 , 0 =
-;e, *
., H N% H N H-,N.-,N1(1),,,N 'NI\T)N .N 4 .,N N
I 0 =', 0 I 0 I
0 ' 0 , , 0 =
, , *
.
H1r H41 H N'1 *.N. T
-.,N N
. I 0 ' I 0 ' I
0 =
0 = 0 = 0 , N ' .N..........õN i *XNN)( = NI-\1)(j':*
I 0 'I 0 / I 0 ' 0 , , 0 , 0 =
N
HIrri 0 and5 , wherein the dashed line marked with the asterisk indicates attachment to T of formula (I) and the unmarked dashed line indicates attachment to the rest of the compound comprising the moiety of formula (I).
In another preferred embodiment, if PG of formula (I) is used for the reversible protection of an amine functional group, PG of formula (I) preferably comprises a moiety of formula (Aa), (Ab) or (Ac):
[R4 ]
Y1 X Y5 i 11 ' )'\ _________________ Y2 , Nu -W- Y3Y4 ____________ R3 Ar (Aa), [R4 \,]n X--\--Yi r R2 Y5 11 ' Nu -W- Y4)\ _________ Y2 __ 0) ________________ R3 Y3 ;
Ar (Ab), [R4 ]

i Nu' ¨W - Y4 y2 R
Ar (Ac), wherein the dashed line marked with the asterisk indicates attachment to T of formula (I) and the unmarked dashed line indicates attachment to the nitrogen of an amine functional group;
n is 0, 1, 2, 3, or 4;
-X- is a chemical bond or a spacer;
=Y1 is selected from the group consisting of =0 and =S;
-Y2- is selected from the group consisting of -0- and -S-;
-Y3-, -Y5- are independently of each other selected from the group consisting of -0-and-S-;
-Y4- is selected from the group consisting of -0-, -NR5- and -C(R6R6a)-;
-R2, -R3, -R4, -R5, -R6, -R6a are independently of each other selected from the group consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl;
-W- is selected from the group consisting of C1_20 alkyl optionally interrupted by one or more groups selected from the group consisting of -0-, -S- and -N(R7)-;
-Nu is a nucleophile selected from the group consisting of -N(R7R7a), -N(R7OH), -N(R7)-N(R7aR7b), -S(R7),-COOH, I N I
' ' , ' N N NJ NT 5 _L 5 N
N
7"- -N
N¨N and -Nu' is a nucleophile selected from the group consisting of -N(R7)-, -N(OH)-, -N(R7)-N(R7a)-, -S-,-C(0)0-, I I
N, , ' N N _L N
' N 9 C>c' 071\1 Ni and wherein the unmarked dashed line indicates attachment to the rest of the moiety of formula (Ac) and the dashed line marked with the asterisk indicates attachment to T of formula (I);
-Ar- is selected from the group consisting of N) N
)<N

(N) /
N' N,N , 101 10:10 10,101 Z\%
wherein ss wherein dashed lines indicate attachment to the rest of the prodrug, -Z1- is selected from the group consisting of-O-, -S- and -N(R7)-, and -Z2- is -N(R7)-; and -R7, -R7a, -R7b are independently of each other selected from the group consisting of -H, C1_6 alkyl, C2_6 alkenyl and C2_6 alkynyl;
wherein the moiety of formula (Aa), (Ab) and (Ac) is optionally further substituted.
It is understood that "the nitrogen of an amine functional group" refers to the amine functional group protected by the protecting group PG.
In another preferred embodiment, if PG of formula (I) is used for the reversible protection of an amine functional group, PG of formula (I) preferably comprises a moiety of formula (Ba), (Bb) and (Bc):

R2 ¨O _________________ R7 RyN
X
R2 ¨O _________________ (Ba) *
- - - - -R2 ¨O _________________ R8 R61 1 :
R7 RyN

R2 ¨O ___________________________________ (Bb) *

R2 ¨O ________________ 8 , R7 R5/ ' R2 ¨O __________________________________ (Bc) , wherein the dashed line marked with the asterisk indicates attachment to T of formula (I) and 5 the unmarked dashed line indicates attachment to the nitrogen of an amine functional group;
X is a spacer moiety such as R13-Y1;
Y1 is 0, S, NR6, succinimide, maleimide, unsaturated carbon-carbon bonds or any heteroatom-containing a free electron pair or is absent;
10 R13 is selected from substituted or non-substituted linear, branched or cyclical alkyl or heteroalkyl, aryls, substituted aryls, substituted or non-substituted heteroaryls;
R2 and R3 are selected independently from hydrogen, acyl groups, or protecting groups for hydroxyl groups;
15 R4 to R12 are selected independently from hydrogen, substituted or non-substituted linear, branched or cyclical alkyl or heteroalkyl, aryls, substituted aryls, substituted or non-substituted heteroaryls, cyano, nitro, halogen, carboxy, carboxamide; and wherein the moiety of formula (Ba), (Bb) and (Bc) is optionally further substituted.

It is understood that "the nitrogen of an amine functional group" refers to the amine functional group protected by the protecting group PG.
In another preferred embodiment, if PG of formula (I) is used for the reversible protection of an amine functional group, PG of formula (I) preferably comprises a moiety of formula (C):
3a R
0 R1 Rla *
3 N x2 ;le R2/ R2a I
0 (C) wherein the dashed line marked with the asterisk indicates attachment to T of formula (I) and the unmarked dashed line indicates attachment to the nitrogen of an amine functional group;
X is c (R4R4a); N(R4); 0; c (R4R4a)_c (R5R5 a);
c(R5R5a)_c(R4R4a); c(R4R4a)_ N(R6); N(R6)_c(R4R4a); c(R4 ¨ 4a K ) 0; or 0-C(R4R4a);
Xl is C; or S(0);
X2 is C(R7, R7a); or C(R7, R7a)-C(R8, R8a);
R15 Ri a, R25 R2a, R35 R3 a5 R4, R4a R55 R.5% R65 R75 R7a, R85 ¨ 8a K are independently selected from the group consisting of H; and C1_4 alkyl;
optionally, one or more of the pair(s) R1 a/R4a, R1 a/RS% R4a/R5a, R4a/R5a, R7a/R8 a form a chemical bond;
optionally, one or more of the pair(s) RI/RI% R2/R2a, R4/R4a, RS/R5% R7/R7a, R8/R8 a are joined together with the atom to which they are attached to form a C3_8 cycloalkyl; or 4- to 7-membered heterocyclyl;
optionally, one or more of the pair(s) Ri/R4 5 Ri /R5 5 R 1 /R65 R4/IR5 5 R7/IR8 5 R2 ¨ 3 /K are joined together with the atoms to which they are attached to form a ring A;
optionally, R3/R3a are joined together with the nitrogen atom to which they are attached to form a 4- to 7-membered heterocycle;

A is selected from the group consisting of phenyl; naphthyl;
indenyl; indanyl;
tetralinyl; C3_10 cycloalkyl; 4- to 7-membered heterocyclyl; and 8- to 1 1 -membered heterobicyclyl;
provided that one hydrogen of R15 Ri a, R25 R2a5 R35 R3 a5 R45 R4 a5 R55 R5 a5 R65 R75 R7 a5 R8 or R8a is replaced by ¨T of formula (I); and wherein the moiety of formula (C) is optionally further substituted.
It is understood that "the nitrogen of an amine functional group" refers to the amine functional group protected by the protecting group PG.
In another preferred embodiment, if PG of formula (I) is used for the reversible protection of an amine functional group, PG of formula (I) preferably comprises a moiety of formula (D):

* 2 ,1 R
I 2a (D) wherein the dashed line marked with the asterisk indicates attachment to T of formula (I) and the unmarked dashed line indicates attachment to the nitrogen of an amine functional group;
Xl is C(RiRia) or a cyclic fragment selected from C3_8 cycloalkyl, 4- to 7-membered heterocyclyl, phenyl, naphthyl, indenyl, indanyl, tetralinyl, or 8-to 11- membered heterobicyclyl, wherein in case Xl is a cyclic fragment, said cyclic fragment is incorporated into Ll via two adjacent ring atoms and the ring atom of Xl, which is adjacent to the carbon atom of the amide bond, is also a carbon atom;
X2 is a chemical bond or selected from C(R3R3a), N(R3), 0, C(R3R3a)_c(R4R4a), (R3R3 N(R3 C(R4R4a)5 C (R3 R3 a, ) 05 or 0-C(R3R3a), wherein in case Xl is a cyclic fragment, X2 is a chemical bond, C(R3R3a), N(R3) or 0;

optionally, in case Xl is a cyclic fragment and X2 is C(R3R3a), the order of the Xl fragment and the X2 fragment within Ll may be changed and the cyclic fragment is incorporated into Ll via two adjacent ring atoms;
R1, R3 and R4 are independently selected from the group consisting of H, C 1_4 alkyl and ¨N(R5R5a);
Ri a, R25 R3 a, R4a and K5a are independently selected from the group consisting of H, and C _4 alkyl;
R5 is C(0)R6;
R6 is C _4 alkyl;
optionally, one of the pairs R1 a/R4a5 R3a/R4a or R1 a 3a /K form a chemical bond;
provided that one hydrogen of R15 R1 a, R25 R2a R35 R3a R45 R4a R55 R5a or R6 is replaced by -T; and wherein the moiety of formula (D) is optionally further substituted.
It is understood that "the nitrogen of an amine functional group" refers to the amine functional group protected by the protecting group PG.
In another preferred embodiment, if PG of formula (I) is used for the reversible protection of an amine functional group, PG of formula (I) preferably comprises a moiety of formula (E):
R4a (R3a N/KR2a Xi Ri (E) wherein the dashed line marked with the asterisk indicates attachment to T of formula (I) and the unmarked dashed line indicates attachment to the nitrogen of an amine functional group;
X1 is selected from 0, S or CH-Ria;

Rl and Ria are independently selected from H, OH, CH3;
R25 K¨ 2a5 R4 and R4a are independently selected from H and C1_4 alkyl, R3 and R3a are independently selected from H, C1_4 alkyl, and R5;
R5 is selected from , , , : ! , , , ' : \ S 1 ) S H

¨7\
: . 0 H 0 1 ___________ :
OH '\ 0 H2 N : \ N H 2 , :\ ___________________________________________ : \ N H 2 \ __ N H2 \
N
H µ
, N H , , , , , , ' \
N
OH 1\T

N
H
wherein dashed lines indicate attachment to the rest of the moiety.
provided that one hydrogen of R1, Ri a, R25 R2a5 R35 R3 a, R45 R4a and R5 is replaced by ¨
T; and wherein the moiety of formula (E) is optionally further substituted.
It is understood that "the nitrogen of an amine functional group" refers to the amine functional group protected by the protecting group PG.
If PG of formula (I) is used for the reversible protection of a carboxyl functional group, PG is preferably selected from the group consisting of i . IL
,, ' III / * ..
= - - ,, :
5 5 and 5 wherein the dashed line marked with the asterisk indicates attachment to T of formula (I) and the unmarked dashed line indicates attachment to the rest of the compound 5 comprising the moiety of formula (I).
Another aspect of the present invention is a compound comprising a moiety of formula (II) T - PG - Xl- L -; (II), wherein 10 the dashed line indicates attachment to the rest of the compound;
T and PG are used as defined in formula (I);
Xl is a linkage;
L is a bond or a spacer moiety.
15 Preferred embodiments of T and PG of formula (II) are as described for formula (I).
Preferably, Xl of formula (II) is a linkage selected from the group consisting of -10-1, -I-S- -Nj- -IN -S-S-15 N=N+
. . , , 5 , 15 I 15 I
li I 5 R-, I , , I , , I I, , I II I I , , II , ,C, 5 .C, 5 IC, 5 C, , , 5 1C-0,5 IC-N:5 , I , , I I , , I I . , I I , N-C-5 ,-N-C-N-5 -HNI-C-N-5 -N-C-0-5 II

R I
I
0 Rla R1 Rla R1 1 II 1 'Nr., 0 C-N, -S ' N
I\
I 1 5 and '2/
R
20 wherein dashed lines indicate attachment to the remainder of the moiety of formula (II), and Rl and Ria are independently of each other selected from H and Ci _6 alkyl.
More preferably, Xl of formula (II) is selected from the group consisting of -b-NH¨, , I II, ¨h C¨N¨H, and ¨hNI_H ;
11. 11.

wherein dashed lines indicate attachment to the remainder of the moiety of formula (II), and Rl and Ria are independently of each other selected from H and Ci _6 alkyl.
Most preferably Xl of formula (II) is In a preferred embodiment PG of formula (II) is selected from formulas (i), (ii), (iii), (iv) or (v) and Xl of formula (II) is =
-HS-H
In a particularly preferred embodiment PG of formula (II) is of formula (i) and Xl of formula (II) is =
-HS-H
In an even more preferred embodiment PG of formula (II) is N S;
wherein the dashed line marked with an asterisk indicates attachment to T of formula (II) and the unmarked dashed line indicates attachment to Xl of formula (II);
and Xl of formula (II) is -HS-17 =
Even more preferably, PG of formula (II) is wherein the dashed line marked with an asterisk indicates attachment to T of formula (II) and the unmarked dashed line indicates attachment to Xl of formula (II);
and Xl of formula (II) is ¨HS¨H =
In one embodiment, L of formula (II) is a chemical bond.
In another embodiment L of formula (II) is a spacer moiety. Any spacer moiety known in the art is a suitable spacer moiety, provided that no heteroatom of L is directly attached to a heteroatom of Xl.
In a preferred embodiment L of formula (II) is a reversible prodrug linker moiety. Suitable reversible prodrug linker moieties are known in the art. Preferred reversible prodrug linker moieties are those disclosed in W02005/099768 A, W02006/136586 A, W02009/095479 A, W02011/012722 A, W02011/089214 A, W02011/089216 A, W02011/089215 A, and W02013/024053A which are hereby incorporated by reference.
Particularly preferred is a reversible prodrug linker moiety as disclosed in W02005/099768A.
Accordingly, a preferred moiety L of formula (II) is of formula (b-i) or (b-ii) [R4], x/s* y5 Y
2 0 ____________________________________ v 3 __ .
Nu¨W¨ Y 4 R3 (b-i), [R4], Y

Y2-1 ___________________________________ y ___ _ 3 W- 4 -Ar-/ R3 (b-ii), wherein the dashed line marked with the asterisk indicates attachment to Xl of formula (II) and the unmarked dashed line indicates attachment to the rest of the compound comprising the moiety of formula (II) , which moiety of formula (b-i) or (b-ii) is attached to the rest of the compound through an amine functional group of said rest of the compound by forming a linkage -Y3-(C=Y5)-NH- between L and the rest of the compound comprising the moiety of formula (II);
X of formula (b-i) or (b-ii) is a spacer moiety such as R5-Y6;
Yi, Y2 of formula (b-i) or (b-ii) are independent of each 0, S, or NR6;
Y3, Y5 of formula (b-i) or (b-ii) are independent of each other 0 or S;
Y4 of formula (b-i) or (b-ii) is 0, NR6 or ¨C(R7)(R8)-;
Y6 of formula (b-i) or (b-ii) is 0, S, NR6, succinimide, maleimide, unsaturated carbon-carbon bonds or any heteroatom containing a free electron pair or is absent;
R2 and R3 of formula (b-i) or (b-ii) are selected independently of each other from hydrogen, substituted or non-substituted linear, branched or cyclical alkyl or heteroalkyl, aryls, substituted aryls, substituted or non-substituted heteroaryls, cyano, nitro, halogen, carboxy, carboxyalkyl, alkylcarbonyl, or carboxamidoalkyl;
R4 of formula (b-i) or (b-ii) is selected independently from hydrogen, substituted or non-substituted linear, branched or cyclical alkyl or heteroalkyl, aryl, substituted aryl, substituted or non-substituted heteroaryl, substituted or non-substituted linear, branched, or cyclical alkoxy, substituted or non-substituted linear, branched, or cyclical heteroalkyloxy, aryloxy, or heteroaryloxy, cyano, halogen;
R5 of formula (b-i) or (b-ii) is selected from substituted or non-substituted linear, branched or cyclical alkyl or heteroalkyl, aryls, substituted aryls, substituted or non-substituted heteroaryls;

R6 of formula (b-i) or (b-ii) is selected from hydrogen, substituted or non-substituted linear, branched or cyclical alkyl or heteroalkyl, aryls, substituted or non-substituted heteroaryls;
R7 and R8 of formula (b-i) or (b-ii) are independently of each other selected from hydrogen, substituted or non-substituted linear, branched or cyclical alkyl or heteroalkyl, aryls, substituted aryls, substituted or non-substituted heteroaryls, carboxyalkyl, alkylcarbonyl, carboxamidoalkyl, cyano, or halogen;
W of formula (b-i) or (b-ii) is selected from substituted or non-substituted linear, branched or cyclical alkyls, aryls, substituted aryls, substituted or non-substituted linear, branched or cyclical heteroalkyl, substituted or nonsubstituted heteroaryls;
Nu of formula (b-i) or (b-ii) is a nucleophile;
n of formula (b-i) or (b-ii) is zero or a positive integer; and Ar of formula (b-i) or (b-ii) is a multi-substituted aromatic hydrocarbon or a multi-substituted aromatic heterocycle.
Optionally, L of formula (b-i) or (b-ii) is further substituted.
Preferably, Y5 of formula (b-i) or (b-ii) is 0.
Preferably, Y3 of formula (b-i) or (b-ii) is 0.
Preferably, R2, R3 and R4 of formula (b-i) or (b-ii) are independently of each other selected from H, C1_6 alkyl, C2_6 alkenyl or C2_6 alkynyl, which Ci_6 alkyl, C2_6 alkenyl or C2_6 alkynyl are optionally further substituted.
Preferably, Yi of formula (b-i) or (b-ii) is 0.
Preferably, Y2 of formula (b-i) or (b-ii) is 0.
Preferably, Y4 of formula (b-i) or (b-ii) is NR6. Preferably, R6 is H or Ci_6 alkyl.
Preferably, Ar of formula (b-i) or (b-ii) is selected from the group consisting of )71 N N N w N
N
wq----N N
n 1 1.1 1.1 == OS and 00 , wherein W is selected from 0, S or N; and W' is N.

Preferably, the moiety Yi Nu¨W¨Y4 ll of formula (b-i) or (b-ii) is selected from the group consisting of R9 [ R111 0 9 R
N ________________________ N N¨WI \

/ I /
R10 R12 mR6 R10 R7 and , 10 wherein W is used as defined above;
m is 2, 3, 4õ5 ,6 ,7 8, 9, or 10;
R9, R10, R11 and R12 are independently of each other selected from H, Ci_6 alkyl, C2_6 alkenyl and C2_6 alkynyl, and which Ci_6 alkyl, C2_6 alkenyl and C2_6 alkynyl are optionally 15 further substituted.

Particularly preferred is a reversible prodrug linker moiety as disclosed in W02009/095479A.
Accordingly, a preferred moiety L of formula (II) is of formula (b-iii) 3a AT3 1 la R
RR
_____________________ 3 ,N X2 X7)cX
2 R2a H* 0 (b-iii), wherein the dashed line with marked with the asterisk indicates attachment to Xl of formula (II) and the unmarked dashed line indicates attachment to the rest of the compound comprising the moiety of formula (II), which moiety of formula (b-iii) is attached to the rest of the compound through an amine functional group provided by said rest of the compound by forming an amide linkage between L and the rest of the compound comprising the moiety of formula (II);
X of formula (b-iii) is C(R
4R4a); N(R4); 0; c(R4R4a)_c(R5R5a); c(R5R5a)_c(R4R4a);
(R4R4a)_N(R6); N(R6)_c (R4R4a); c (R4- 4a, K ) 0; or 0-C(R4R4a);
Xl of formula (b-iii) is C; or S(0);
X2 of formula (b-iii) is C(R7, R7a); or C(R7, R7a)-C(R8, R8a);
X3 of formula (b-iii) is 0; S; or N-CN;
R15 Ri a, R25 R2a, R3 R3 a5 R45 R4a5 R55 R5 a5 R65 R75 R7a5 R85 ¨ 8a K of formula (b-iii) are independent of each other selected from the group consisting of H; and Ci _4 alkyl;
optionally, one or more of the pairs R1 a/R4a, Rh/R5% R4a/R5a, R7a/K ¨ 8a of formula (b-iii) form a chemical bond;
optionally, one or more of the pairs RI/RI% R2/R2a, R4/R4a, RS/R5% R7/R7a, R8/R8 a of formula (b-iii) are joined together with the atom to which they are attached to form a C3_10 cycloalkyl; or 4- to 7-membered heterocyclyl;
optionally, one or more of the pairs R'/R4, R 1 /R55 R 1 /R65 R4/R5, R4/R6, R7/R8, of formula (b-iii) are joined together with the atoms to which they are attached to form a ring A;
optionally, R3/R3a of formula (b-iii) are joined together with the nitrogen atom to which they are attached to form a 4- to 7-membered heterocycle;

A of formula (b-iii) is selected from the group consisting of phenyl;
naphthyl; indenyl;
indanyl; tetralinyl; C3_10 cycloalkyl; 4- to 7-membered heterocyclyl; and 8-to 11-membered heterobicyclyl; and wherein the moiety of formula (b-iii) is substituted with Xl of formula (II) and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (b-iii) is not replaced and that R3 and R3a of formula (b-iii) are independently of each other H or are connected to N through an SP3-hybridized carbon atom.
Preferably, X3 of formula (b-iii) is 0.
Preferably, X of formula (b-iii) is N(R4), Xl of formula (b-iii) is C and X3 of formula (b-iii) is 0.
Preferably, X2 of formula (b-iii) is C(R7R7a).
It is understood that the moieties of formula (b-i), (b-ii) and (b-iii) may optionally comprise functional groups for the conjugation of further groups, such as for example polymer carriers.
Another aspect of the present invention is a compound comprising a moiety of formula (Ha) T ¨ PG ¨ L2¨ Ll (Ha), wherein the dashed line indicates attachment to the rest of the compound;
T and PG are used as defined in formula (I);
L2 is a chemical bond or a spacer moiety;
Ll reversible prodrug linker moiety.
Preferred embodiments of T and PG of formula (Ha) are as described for formula (I).
In one embodiment L2 of formula (Ha) L2 is a chemical bond.
In a preferred embodiment L2 of formula (Ha) is selected from -T-5 -C(0)0-5 -0-, -C(0)-5 -C(0)N(RY1)-5 -S(0)2N(RY1)-5 -S(0)N(RY1)-5 -S(0)2-5 -S(0)-5 -N(RY1)S(0)2N(RY1a)-5 -S-5 -N(RY1)-5 -0C(ORY1)(Ry 1 a)_, _N(Ryl )c(0)N(Ry 1 a) _, _ OC(0)N(RY1)-5 C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl; wherein -T-5 Ci_20 alkyl, C2_20 alkenyl, and C2_20 alkynyl are optionally substituted with one or more RY25 which are the same or different and wherein C1_20 alkyl, C2_ 20 alkenyl, and C2_20 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-5 -C(0)0-5 -0-, -C(0)-5 -C(0)N(RY3)-5 -S(0)2N(RY3)--S(0)N(RY3)-5 -S(0)2-5 -S(0)-5 -N(RY3)S(0)2N(RY3a)-5 -S-5 -N(RY3)-5 -0C(ORY3)(RY3a)-5 -N(RY3)C(0)N(RY3a)-5 and -0C(0)N(RY3)-;
RY1 and RYla are independently of each other selected from the group consisting of -H, -T, Ci_io alkyl, C2_10 alkenyl, and C2_10 alkynyl; wherein -T, Ci_io alkyl, C2_10 alkenyl, and C2-10 alkynyl are optionally substituted with one or more RY25 which are the same or different, and wherein C1_10 alkyl, C2_10 alkenyl, and C2_10 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-5 -C(0)0-5 -0-, -C(0)-5 -C(0)N(RY4)-5 -S(0)2N(RY4)-5 -S(0)N(RY4)-5 -S(0)2-5 -S(0)-5 -N(RY4)S(0)2N(RY4a)-5 -S-5 -N(RY4)-5 -0C(ORY4)(Ry4a)_5 _N(Ry4)c("(¨K) y4a,_ 5 and -0C(0)N(RY4)-;
each T is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3_10 cycloalkyl, 3- to l0-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl;
wherein each T is independently optionally substituted with one or more RY25 which are the same or different;
RY2 is selected from the group consisting of halogen, -CN, oxo (=0), -COORY55 --C(0)RY55 -C(0)N(RY5RY5a), -S(0)2N(RY5RY5a), -S(0)N(RY5RY5a), -s(o)2R55 -S(0)RY55 -N(RY5)S(0)2N(RY5aRY5b), -SRY55 -N(RY5RY5a), NO2 -0c(0)R5, -N(RY5)C(0)RY5a5 -N(RY5)S(0)2RY5a5 -N(RY5)S(0)RY5a5 -N(RY5)C(0)ORY5a5 -N(RY5)C(0)N(RY5aRY5b), -0C(0)N(RY5RY5a), and C1_6 alkyl; wherein C1_6 alkyl is optionally substituted with one or more halogen, which are the same or different; and each RY35 Ry3a, Ry45 K RY55 RY5a and RY5b is independently of each other selected from the group consisting of -H, and C1_6 alkyl; wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different.
Even more preferably, L2 of formula (Ha) is selected from the group consisting of -T-5 -C(0)0-5 -0-, -C(0)-5 -C(0)N(RY1)-5 -S(0)2N(RY1)-5 -S(0)N(RY1)-5 -S(0)2-5 -S(0)-5 -N(RY1)S(0)2N(RY1a)-5 -S-5 -N(RY1)-5 -0C(ORY1)(Ryla)_, _N(Ryl)c(0)N(Ryla,_ ) _, OC(0)N(RY1)-5 C1_50 alkyl, C2_50 alkenyl, and C2_50 alkynyl; wherein -T-5 C1_20 alkyl, C2_20 alkenyl, and C2-20 alkynyl are optionally substituted with one or more RY25 which are the same or different and wherein C1_20 alkyl, C2_20 alkenyl, and C2_20 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-5 -C(0)0-, -0-, -C(0)-, -C(0)N(RY3)-, -S(0)2N(RY3)-, -S(0)N(RY3)-, -S(0)2-, -S(0)-, -N(RY3)S(0)2N(RY3a)-5 -S-5 -N(RY3)-5 -0C(ORY3)(RY3a)-, -N(RY3)C(0)N(RY3a)-, and -0C(0)N(RY3)-;
RY1 and RYla are independently selected from the group consisting of -H, -T, Ci_10 alkyl, C2-10 alkenyl, and C2_10 alkynyl;
each T is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl;
each RY2 is independently selected from the group consisting of halogen, and C1_6 alkyl; and each RY35 Ry3a5 Ry45 -.y4a., K RY55 RY5a and RY5b is independently of each other selected from the group consisting of -H, and C1_6 alkyl; wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different.
Even more preferably, L2 of formula (Ha) is a C1_20 alkyl chain, which is optionally interrupted by one or more groups independently selected from -0-, -T- and -C(0)N(Riaa)-;
and which C1_20 alkyl chain is optionally substituted with one or more groups independently selected from -OH, -T and -C(0)N(RY6RY6a); wherein RY65 RY6a are independently selected from the group consisting of H and C1_4 alkyl and wherein T is selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3_10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl.
Preferably, L2 of formula (Ha) has a molecular weight in the range of from 14 g/mol to 750 g/mol.

In a preferred embodiment Ll of formula (Ha) is a reversible prodrug linker moiety. Suitable reversible prodrug linker moieties are known in the art. Preferred reversible prodrug linker moieties are those disclosed in W02005/099768 A, W02006/136586 A, W02009/095479 A, W02011/012722 A, W02011/089214 A, W02011/089216 A, W02011/089215 A, and 5 W02013/024053A which are hereby incorporated by reference.
Particularly preferred is a reversible prodrug linker moiety as disclosed in W02005/099768A.
Accordingly, a preferred moiety Ll of formula (Ha) comprises a moiety of formula (b-i) or (b-ii) [R4], Y x/s* y5 Y2 *Q) ________________________________ y3 , 11 :
_ Nu¨W¨Y-4 R3 10 (b-i), , [R4], y c------- R2 Y5 Y2A 0 i _____________________________________ Y3 11 :

NW¨Y4 -Ai'..- R3 ' (b-ii), wherein the dashed line marked with the asterisk indicates attachment to L2 of formula (Ha) and the unmarked dashed line indicates attachment to the rest of the compound 15 comprising the moiety of formula (Ha) , which moiety of formula (b-i) or (b-ii) is attached to the rest of the compound through an amine functional group of said rest of the compound by forming a linkage -Y3-(C=Y5)-NH- between L and the rest of the compound comprising the moiety of formula (Ha);
X of formula (b-i) or (b-ii) is a spacer moiety such as R5-Y6;
20 Yl, Y2 of formula (b-i) or (b-ii) are independent of each 0, S, or NR6;
Y3, Y5 of formula (b-i) or (b-ii) are independent of each other 0 or S;
Y4 of formula (b-i) or (b-ii) is 0, NR6 or ¨C(R7)(R8)-;
Y6 of formula (b-i) or (b-ii) is 0, S, NR6, succinimide, maleimide, unsaturated carbon-carbon bonds or any heteroatom containing a free electron pair or is absent;
25 R2 and R3 of formula (b-i) or (b-ii) are selected independently of each other from hydrogen, substituted or non-substituted linear, branched or cyclical alkyl or heteroalkyl, aryls, substituted aryls, substituted or non-substituted heteroaryls, cyano, nitro, halogen, carboxy, carboxyalkyl, alkylcarbonyl, or carboxamidoalkyl;
R4 of formula (b-i) or (b-ii) is selected independently from hydrogen, substituted or non-substituted linear, branched or cyclical alkyl or heteroalkyl, aryl, substituted aryl, substituted or non-substituted heteroaryl, substituted or non-substituted linear, branched, or cyclical alkoxy, substituted or non-substituted linear, branched, or cyclical heteroalkyloxy, aryloxy, or heteroaryloxy, cyano, halogen;
R5 of formula (b-i) or (b-ii) is selected from substituted or non-substituted linear, branched or cyclical alkyl or heteroalkyl, aryls, substituted aryls, substituted or non-substituted heteroaryls;
R6 of formula (b-i) or (b-ii) is selected from hydrogen, substituted or non-substituted linear, branched or cyclical alkyl or heteroalkyl, aryls, substituted or non-substituted heteroaryls;
R7 and R8 of formula (b-i) or (b-ii) are independently of each other selected from hydrogen, substituted or non-substituted linear, branched or cyclical alkyl or heteroalkyl, aryls, substituted aryls, substituted or non-substituted heteroaryls, carboxyalkyl, alkylcarbonyl, carboxamidoalkyl, cyano, or halogen;
W of formula (b-i) or (b-ii) is selected from substituted or non-substituted linear, branched or cyclical alkyls, aryls, substituted aryls, substituted or non-substituted linear, branched or cyclical heteroalkyl, substituted or nonsubstituted heteroaryls;
Nu of formula (b-i) or (b-ii) is a nucleophile;
n of formula (b-i) or (b-ii) is zero or a positive integer; and Ar of formula (b-i) or (b-ii) is a multi-substituted aromatic hydrocarbon or a multi-substituted aromatic heterocycle.
Optionally, Ll of formula (b-i) or (b-ii) is further substituted.
Preferably, Y5 of formula (b-i) or (b-ii) is 0.
Preferably, Y3 of formula (b-i) or (b-ii) is 0.
Preferably, R2, R3 and R4 of formula (b-i) or (b-ii) are independently of each other selected from H, C1_6 alkyl, C2_6 alkenyl or C2_6 alkynyl, which Ci_6 alkyl, C2_6 alkenyl or C2_6 alkynyl are optionally further substituted.

Preferably, Yi of formula (b-i) or (b-ii) is 0.
Preferably, Y2 of formula (b-i) or (b-ii) is 0.
Preferably, Y4 of formula (b-i) or (b-ii) is NR6. Preferably, R6 is H or Ci_6 alkyl.
Preferably, Ar of formula (b-i) or (b-ii) is selected from the group consisting of N N w' N, N
jt ,W
/\1 1.1 1.1 10= OS and 00 wherein W is selected from 0, S or N; and W' is N.
Preferably, the moiety Yi Nu¨W¨Y4 ________________ of formula (b-i) or (b-ii) is selected from the group consisting of N¨W __________________________________________________ and 5 wherein W is used as defined above;
m is 2, 3, 4õ5 56 57 8, 9, or 10;
R9, R10, R11 and R12 are independently of each other selected from H, Ci_6 alkyl, C2_6 alkenyl and C2_6 alkynyl, and which Ci_6 alkyl, C2_6 alkenyl and C2_6 alkynyl are optionally further substituted.
Particularly preferred is a reversible prodrug linker moiety as disclosed in W02009/095479A.
Accordingly, a preferred moiety 1_,1 of formula (Ha) comprises a moiety of formula (b-iii) 3a NT3 1 la RR
_____________________ 3 ,N X2 XN7)cX
2 R2a H* 0 (b-iii), wherein the dashed line with marked with the asterisk indicates attachment to L2 of formula (Ha) and the unmarked dashed line indicates attachment to the rest of the compound comprising the moiety of formula (Ha), which moiety of formula (b-iii) is attached to the rest of the compound through an amine functional group provided by said rest of the compound by forming an amide linkage between 1_,1 and the rest of the compound comprising the moiety of formula (Ha);
X of formula (b-iii) is C(R4R4a); N(R4); 0; C(R4R4a)-C(R5R5a); C(R5R5a)-C(R4R4a);
C(R4R4a)-N(R6); N(R6)-C(R4R4a); C(R4R4a)-0; or 0-C(R4R4a);
Xl of formula (b-iii) is C; or S(0);
X2 of formula (b-iii) is C(R7, R7a); or C(R7, R7a)-C(R8, R8a);
X3 of formula (b-iii) is 0; S; or N-CN;
R15 Ri a, R25 R2a5 R35 R3 a, R45 R4a5 R55 R5 a, R65 R75 R7a5 R85 ¨ 8a K of formula (b-iii) are independent of each other selected from the group consisting of H; and C1_4 alkyl;

optionally, one or more of the pairs R1 a/R4a, Rh/R5% R4a/R5a, R7a/K ¨ 8a of formula (b-iii) form a chemical bond;
optionally, one or more of the pairs RI/RI% R2/R2a, R4/R4a, RS/R5% R7/R7a, R8/R8 a of formula (b-iii) are joined together with the atom to which they are attached to form a C3_10 cycloalkyl; or 4- to 7-membered heterocyclyl;
optionally, one or more of the pairs Ri/R4 5 R 1 /R5 5 R 1 /R6 5 R4/R5 5 R4/R6 f formula (b-iii) are joined together with the atoms to which they are attached to form a ring A;
optionally, R3/R3a of formula (b-iii) are joined together with the nitrogen atom to which they are attached to form a 4- to 7-membered heterocycle;
A of formula (b-iii) is selected from the group consisting of phenyl;
naphthyl; indenyl;
indanyl; tetralinyl; C3_10 cycloalkyl; 4- to 7-membered heterocyclyl; and 8-to 11-membered heterobicyclyl; and wherein the moiety of formula (b-iii) is substituted with L2 of formula (Ha) and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (b-iii) is not replaced and that R3 and R3a of formula (b-iii) are independently of each other H or are connected to N through an SP3-hybridized carbon atom.
Preferably, X3 of formula (b-iii) is 0.
Preferably, X of formula (b-iii) is N(R4), Xl of formula (b-iii) is C and X3 of formula (b-iii) is 0.
Preferably, X2 of formula (b-iii) is C(R7R7a).
It is understood that the moieties of formula (b-i), (b-ii) and (b-iii) may optionally comprise functional groups for the conjugation of further groups, such as for example polymer carriers.
Another aspect of the present invention is a conjugate of formula (III) (T ¨ PG ¨ Xl¨ L ¨ X2 )PM (III), wherein T and PG are used as defined in formula (I);

Xl and L are used as defined in formula (II);
X2 is a linkage;
x is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20; and 5 PM is a moiety having a molecular weight of at least 1 kDa.
Preferred embodiments of T and PG are as described for formula (I) and preferred embodiments of Xl and L are as described for formula (II).
10 Preferably, X2 of formula (III) is a linkage selected from the group consisting of -0-1=, -I-S- -II\T-L -IN -S-S-1, -IN=1\14,-I, R1 . .
ORi NRi NR

, I , , I , , I I, , II õ I I
, , II
- , -C-, -C,, -C- , ,-C1-, -C-Co,-, -C-N, , I , . II õ II i , I I , N-C,-, '.-N-C-N-, -HNI-C-N-, -N-C-0-, II

R1 Rla I
R1 RI la . II , .N0 C-N, -S -, N
II , and ' \
R
0;-wherein 15 dashed lines indicate attachment to the remainder of the conjugate of formula (III), and Rl and Ria are independently of each other selected from H and C1_6 alkyl.
More preferably, X2 of formula (III) is selected from the group consisting of , (Iii' , 0 III . ii , , 0 II , . V .
C-04H -1=C-1, N-r, 11-C-ICI, -10-C--1, , V , -Hi:0-C-1--;

R
wherein dashed lines indicate attachment to the remainder of the conjugate of formula (III), and Rl and Ria are independently of each other selected from H and Ci _6 alkyl.
x of formula (III) is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.
Preferably, x of formula (III) is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. More preferably, x of formula (III) is 1, 2, 3, 4, 5 or 6. Even more preferably, x of formula (III) is 1, 2, 3, 4 or 5. Even more preferably, x of formula (III) is 1, 2 or 3. Most preferably, x of formula (III) is 1. If x of formula (III) is 1, the conjugate of formula (III) is referred to as a "monoconjugate".
Another aspect of the present invention is a conjugate of formula (Ma), i.e.
the compound of the present invention is of formula (Ma) (T - PG - L2- Ll )PM (Ma), wherein T and PG are used as defined in formula (I);
Ll and L2 are used as defined in formula (Ha);
x is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20; and PM is a moiety having a molecular weight of at least 1 kDa.
PM of formula (III) or (Ma) is a moiety having a molecular weight of at least 1 kDa, e.g. of at least 2 kDa, of at least 3 kDa, of at least 4 kDa, of at least 5 kDa, of at least 6 kDa, of at least 7 kDa, of at least 8 kDa, of at least 9 kDa, of at least 10 kDa, of at least 12 kDa, of at least 15 kDa, or of at least 20 kDa. Preferably, PM of formula (III) or (Ma) has a molecular weight of at most 1000 kDa, e.g. of at most 900 kDa, of at most 800 kDa, of at most 700 kDa, of at most 600 kDa, of at most 500 kDa, of at most 400 kDa, of at most 300 kDa, of at most 200 kDa or of at most 100 kDa.
Preferably, PM of formula (III) or (Ma) comprises a peptide or protein. More preferably, PM
of formula (III) is a protein. Even more preferably, PM of formula (III) or (Ma) is a protein selected from the group consisting of adrenocorticotropic hormone (ACTH), adenosine deaminase, agalsidase, albumin, alfa-1 antitryp sin (AAT), alfa-1 proteinase inhibitor (API), alglucosidase, alteplase, anistreplase, ancrod serine protease, antibodies (monoclonal or polyclonal and fragments or fusions), antithrombin III, antitrypsins, aprotinin, asparaginases, biphalin, bone-morphogenic proteins, calcitonin (preferably from salmon), collagenase, DNase, endorphins, enfuvirtide, enkephalins, erythropoietins, factor VIIa, factor VIII, factor Villa, factor IX, fibrinolysin, fusion proteins, follicle-stimulating hormones, granulocyte colony stimulating factor (G-CSF), galactosidase, glucagon, glucagon-like peptides like GLP-1, glucocerebrosidase, granulocyte macrophage colony stimulating factor (GM-CSF), chorionic gonadotropin (hCG), hemoglobins, hepatitis B vaccines, hirudin, hyaluronidases, idurnonidase, immune globulins, influenza vaccines, interleukines (1 alfa, 1 beta, 2, 3, 4, 6, 10, 11, 12), IL-1 receptor antagonist (IL- lra), insulins, interferons (alfa 2a, alfa 2b, alfa 2c, beta la, beta lb, gamma la, gamma lb), keratinocyte growth factor (KGF), lactase, leuprolide, levothyroxine, luteinizing hormone, lyme vaccine, natriuretic peptide, pancrelipase, papain, parathyroid hormone, PDGF, pepsin, phospholipase-activating protein (PLAP), platelet activating factor alcetylhydrolase (PAF-AH), prolactin, protein C, octreotide, secretin, sermorelin, superoxide dismutase (SOD), somatropins (growth hormone), somatostatin, streptokinase, sucrase, tetanus toxin fragment, tilactase, thrombins, thymosin, thyroid stimulating hormone, thyrothropin, transforming growth factors, tumor necrosis factor (TNF), TNF receptor-IgG Fc, tissue plasminogen activator (tPA), transferrin, TSH, urate oxidase and urokinase.
In a preferred embodiment PM of formula (III) or (Ma) comprises and antibody or antibody fragment.
Another aspect of the present invention is a method of purification, comprising the steps of (i) Providing a mixture comprising a multitude of conjugates of formula (III) or (Ma) which differ by their value for x;
(ii) Subjecting the mixture of step (i) to a purification method suitable for the tag moiety T; and (iii) Isolating a fraction that comprises compounds of formula (III) or (Ma) in which at least 80% of all compounds of formula (III) or (IIIa) have the same value for x.

The fraction of step (iii) comprises compounds of formula (III) or (Ma) in which at least 80%
of all compounds have the same value for x. Preferably, at least 85% of all compounds have the same value for x, more preferably, at least 90% of all compounds have the same value for x and most preferably at least 92% of all compounds have the same value for x.
In the fraction of step (iii) x is preferably 1 or 2, most preferably x is 1, i.e. the compound of formula (III) or (Ma) is a monoconjugate.
The purification method in step (ii) depends on the tag moiety T of formula (III) or (Ma).
If T of formula (III) or (Ma) is a polymeric moiety with a molecular weight of at least 10 %
(w/w) of PM of formula (III) or (Ma), the purification method of step (ii) is preferably size-exclusion chromatography.
If T of formula (III) or (Ma) comprises an affinity ligand, the purification method of step (ii) is preferably affinity chromatography.
If T of formula (III) or (Ma) comprises a charged moiety, the purification method of step (ii) is preferably ion exchange chromatography.
In a preferred embodiment T of formula (III) or (Ma) is a charged moiety and the purification method of step (ii) is ion exchange chromatography.
Another aspect of the present invention is a monoconjugate obtainable from the method of the present invention in which x in step (iii) is 1.
Fig. 1: Chromatogram (based on absorption at 280 nm) of CIEC purification of tagged Lucentis-linker monoconjugate 4b. 4b could be separated from Lucentis as well as Lucentis-linker bisconjugate. The observed two peaks at 15 cv and 18 cv were identified as 4b by mass spectrometry. Conductivity is shown as grey curve.
Fig. 2: Chromatogram (based on absorption at 280 nm) of CIEC purification of tagged Lucentis-linker monoconjugate 6b. 6b could be separated from Lucentis as well as tagged Lucentis-linker bisconjugate. The observed two peaks at 95 mL and 110 mL were identified as 6b by mass spectrometry. Conductivity is shown in grey.
Materials and Methods Lucentis and Ranibizumab are used synonymously throughout the following examples.
Materials:
TBTU, HATU, PyBOP, and Fmoc-L-Asp(OtBu)-OH were purchased from Merck Biosciences GmbH, Schwalbach/Ts, Germany.
Boc-Lys(Boc)-0Su was purchased from Senn chemicals AG, Dielsdorf, Switzerland.
Fmoc-N-Me-L-Asp(OtBu)-OH was purchased from Bachem, Bubendorf, Switzerland. 1,9-bis-Boc-1,5,9-triazanonan was purchased from PolyPeptide Laboratories A/S, Hillerod, Denmark.
(5-methy1-2-oxo-1,3-dioxo1-4-y1)-methyl 4-nitrophenyl carbonate was purchased from Chemzon Scientific Inc., Lachine, QC, Canada.
All other chemicals were from Sigma-ALDRICH Chemie GmbH, Taufkirchen, Germany.
Methods:
Reactions were performed with dry solvents (DCM, THF, ACN, DMF, dioxane, Me0H, toluene) stored over molecular sieve purchased from Sigma-ALDRICH Chemie GmbH, Taufkirchen, Germany. Generally, reactions were stirred at room temperature and monitored by HPLC/MS or TLC.
RP-HPLC was done on a 100x20 mm or 100x40 mm C18 ReproSil-Pur 300 ODS-3 5g column (Dr. Maisch, Ammerbuch, Germany) or XBridge BEH300 C18 OBD Prep 10 gm 30x150 mm or 5 gm 10x150 mm (Waters, Eschborn, Germany) connected to a Waters 600 or 2535 HPLC System and Waters 2487 or 2489 Absorbance detector, respectively.
Linear gradients of solution A (0.1% TFA in H20) and solution B (0.1% TFA in acetonitrile) were used. HPLC fractions containing product were combined and lyophilized.

Flash chromatography purifications were performed on an Isolera One system from Biotage AB, Sweden, using Biotage KP-Sil silica cartridges and n-heptane, ethyl acetate, and methanol as eluents. Products were detected at 254 nm. For products showing no absorbance above 240 nm fractions were screened by LC/MS.

Analytical ultra-performance LC (UPLC) was performed on a Waters Acquity system equipped with a Waters BEH300 C18 column (2.1 x 50 mm, 1.7 gm particle size) coupled to a LTQ Orbitrap Discovery mass spectrometer from Thermo Scientific.
10 HPLC-Electrospray ionization mass spectrometry (HPLC-ESI-MS) was performed on a Waters Acquity UPLC with an Acquity PDA detector coupled to a Thermo LTQ
Orbitrap Discovery high resolution/high accuracy mass spectrometer or Waters Micromass ZQ both equipped with a Waters ACQUITY UPLC BEH300 C18 RP column (2.1 x 50 mm, 300 A, 1.7 [tm, flow: 0.25 mL/min; solvent A: UP-H20 + 0.04% TFA, solvent B: UP-Acetonitrile +
15 0.05% TFA.
Buffer exchange was performed on a HiTrap or HiPrep column (GE Healthcare) connected to an Aekta Purifier system.
20 Cationic ion exchange chromatography was performed either on a Source 15S 4.6/100 column or on a Source 15 S 6 mL column connected to an Aekta Purifier system using 20 mM MES, pH 5.7 and 20 mM MES, 500 mM NaC1, pH 5.7 as mobile phase A and B, respectively.
25 Example 1 Synthesis of linker reagent 1k Linker reagent 1k was synthesized according to the following scheme:

Boo_ N 0 N¨ Boc' N
I\1-H 0 0() 00() ,. H _,..
Boc_Nkc H2N---1\1---/ / H
Trt, S Trt, S ld lc la lb Trt, S Trt, S

O 0,_0(:) H N,, )L0 H 0 '1 0 0 T
0,, T le H N ,, A N.1\1 O H H N, I\
,)LNc OtBu I / ¨ H3.- - /
OtBu lf OtBu lg _____________ V.
Trt, S *"S H
I
0 kit *3 TFA-O0,0,)--,..,.
0 'f 0 0 H N,=)I-NN H 2 -1.
O H H
OtBu ___________________________________________________________ 3w lh ` ' s-s^N' ___/ 1 Oy H N ,=)LN.1\c C) H
OtBu H H 0 I ij *3 TFA-S' S le ..4 o 1 1\1 L

'f H N,= --I- N ----,...-- N --.

o OH
0 lk o `s ' --SI\K *3 TFA-N-Boc-ethylenediamine (0.77 g, 4.8 mmol) was dissolved in DCM (15 mL) and 6-tritylmercaptohexanoic acid (2.25 g, 5.76 mmol) and PyBOP (3.0 g 5.76 mmol) were added with stirring. DIPEA (2.52 ml, 14.4 mmol) was added and the reaction stirred for 1 h. The reaction was diluted with diethyl ether (150 mL) and washed with slightly basic brine (3x30 mL, prepared from 100 mL brine and 3 mL 0.1 M aq. NaOH). The organic phase was washed once more with brine (30 mL), dried over Na2SO4 and concentrated in vacuo and purified using flash chromatography to give la as a white foam. Yield: 2.55 g (4.79 mmol, 99%) MS:
m/z 555.24 = [M+Na] ', (calculated = 555.27).
la (2.55 g, 4.79 mmol) was dissolved in THF (26 mL) and transferred into an oven-dried argon filled round-bottom flask. Borane - THF complex in THF (1 M, 17.7 mL, 17.71 mmol) was added and the reaction stirred for 15 h. Me0H (5.4 mL) was added slowly and N,N' -dimethyl ethylenediamine (3.11 mL, 28.8 mmol) was added and the reaction refluxed for 2.5 h. After cooling the reaction was diluted with ethyl acetate and washed with sat. sodium bicarbonate solution (2x125 mL) and brine (1x125 mL). The organic phase was dried over Na2SO4, concentrated in vacuo to give lb which was used without further purification in the next step. Yield: 2.38 g (4.59 mmol, 96%) MS:
m/z 519.27 = [M+H] ', (calculated =
519.31).
lb (1.19 g 2.29 mmol) was dissolved in DCM and (5-methyl-2-oxo-1,3-dioxo1-4-y1)-methyl 4-nitrophenyl carbonate (1.02 g, 3.44 mmol) and 2,4,6-collidine (1.36 mL, 10.32 mmol) were added and the reaction stirred for 23 h. The reaction was concentrated in vacuo and purified using flash chromatography to give lc. Yield: 1.19 g (1.77 mmol, 79%) MS:
m/z 697.18 =
[M+Na] ', (calculated = 697.29).
lc (0.5 g, 0.74 mmol) was dissolved in DCM (2.5 mL) and triphenylmethanol (0.19 g, 0.74 mmol) and TFA (2.5 mL) were added. The reaction was stirred for 40 min, concentrated in a stream of argon and dried in vacuo (< 0.1 mbar). The residue was dissolved in ACN/water (7:3 v/v, 10 mL) and purified by RP-HPLC to give ld (0.50 g, 0.84 mmol, 114 %). MS: m/z 575.33= [M+H] ', (calculated = 575.26).
2-Chlorotritylchloride resin (1.22 mmol/g, 0.87 g, 1 mmol) was weighted into a 10 ml syringe with fit. The resin was swollen with 5 mL DCM and washed with DCM (5x4 mL). N-Fmoc-L-Asp(OtBu)-OH (1.1 g, 2.7 mmol) was dissolved in DCM (5 mL) and DIPEA (0.66 mL, 3.78 mmol) was added and the solution drawn into the syringe. The syringe was agitated for 1 h. Me0H (0.5 mL) was drawn into the syringe and the syringe agitated for 15 min. The resin was washed 5 times with DCM (4 mL) and 5 times with DMF (5 mL). The resin was agitated 3 times for 5 min with DMF:DBU:piperidine (96:2:2 v/v/v 4 mL). The resin was washed 5 times with DMF (4 mL). Acetic anhydride (0.51 mL, 5.4 mmol) and DIPEA (1.9 mL, 10.8 mmol) were dissolved in DMF (6 mL) and the solution was drawn into the syringe and the syringe agitated for 15 min. The resin was washed 5 times with DMF (4 mL), 5 times with DCM (4 mL). A solution of HFIP/DCM (1/4 v/v, 5 mL each) were drawn into the syringe and the syringe agitated 3 times for 10 min. The collected filtrates were concentrated in vacuo.
Crude le (0.29 g, 1.23 mmol, 114 %) was used without further purification in the next step.
MS: m/z 254.38= [M+Na]', (calculated = 254.12).
le (65 mg, 0.28 mmol) was dissolved in DCM (3 mL) and PyBOP (0.18 g, 0.34 mmol) and DIPEA (0.15 mL, 0.84 mmol) were added. id (0.18 g, 0.31 mmol) was dissolved in DCM (3 mL) and added to the reaction. The reaction was stirred for lh and concentrated in vacuo. The residue was purified by RP-HPLC to give if (97 mg, 0.12 mmol, 44 %). MS: m/z 810.02=
[M+Na]', (calculated = 810.34).
if (200 mg, 0.25 mmol) were dissolved in HFIP (5 mL) and TES (0.3 mL) and AcOH
(0.3 mL) were added and the reaction stirred for 75 min. The solvents were removed in a stream of argon and the residue dissolved in ACN/water (9:1 v/v) and purified by RP-HPLC
to give lg (95 mg, 0.17 mmol, 68 %). MS: m/z 568.28= [M+Na]', (calculated = 568.23).
lg (95 mg, 0.17 mmol) was dissolved in ACN/water (1:1 v/v, 3 mL) and 6, 6'-dithiodinicotinic acid (107 mg, 0.35 mmol) was added. ACN (1 mL) was added to improve solubility and pH 7.4 sodium phosphate buffer (0.5 M, 1.5 mL) was added to adjust the pH.
The reaction was stirred for 45 min and the reaction mixture directly purified by RP-HPLC to give lh (103 mg, 0.15 mmol, 85 %). MS: m/z 699.14= [M+H]', (calculated =
699.22).
Fmoc protected Sieber amide resin (0.74 mg, 0.45 mmol, 0.61 mmol/g) was weighed into a 20 ml, syringe equipped with a filter fit. The resin was swollen with DMF (2 x 10 mL, 2 x 15 min) and the Fmoc protecting group was afterwards removed by shaking the resin with DMF/piperidine/DBU (98:1:1, v/v/v, 2 x 8 mL, 1 x 5 min, 1 x 10 min). After intensive washing with DMF (10 x 8 mL) the first coupling was accomplished by incubating the resin for 1 h with a solution of Fmoc-L-Lys(Me3C1)-OH (0.5 g, 1.12 mmol), HOBt (0.17 g, 1.12 mmol), HATU (0.43 g, 1.12 mmol) and DIPEA (0.78 mL, 4.5 mmol) in DMF (4 mL).
After intense washing with DMF (10 x 8 mL) the terminal Fmoc protecting group was removed by treating the resin with DMF/piperidine/DBU (98:1:1, v/v/v, 2 x 8 mL, 1 x 5 min, 1 x 10 min).
The resin was washed with DMF (10 x 8 mL) and the second amino acid was attached by incubating the resin for 1 h with a solution of Fmoc-L-Lys(Me3C1)-OH (0.5 g, 1.12 mmol), HOBt (0.17 g, 1.12 mmol), TBTU (0.36 g, 1.12 mmol) and DIPEA (0.78 mL, 4.5 mmol) in DMF (4 mL). After washing with DMF (10 x 8 mL) the Fmoc protecting group was removed by incubation with DMF/piperidine/DBU (98:1:1, v/v/v, 2 x 8 mL, 1 x 5 min, 1 x 10 min).
After washing with DMF (10 x 8 mL) the amount of resin was halved and one part of the resin was kept aside. The next coupling was accomplished by incubating the resin for 1 h with a solution of Fmoc-L-Lys(Me3C1)-OH (0.25 g, 0.56 mmol), HOBt (86 mg, 0.56 mmol), TBTU (0.18 g, 0.56 mmol) and DIPEA (0.39 mL, 2.25 mmol) in DMF (2 m1). After washing with DMF (10 x 4 mL) and subsequent deprotection with DMF/piperidine/DBU
(98:1:1, v/v/v, 2 x 4 mL, 1 x 5 min, 1 x 10 min) and washing with DMF (10 x 4 mL) the resin was treated with a coupling solution of Fmoc-Ado-OH (0.22 g, 0.56 mmol), HOBt (86 mg, 0.56 mmol), TBTU (0.18 g, 0.56 mmol) and DIPEA (0.39 mL, 2.25 mmol) in DMF (2 mL).
The resin was washed with DMF (10 x 4 mL) and deprotected with DMF/piperidine (4:1 v/v, 2 x 4 mL, 1 x 15 min, 1 x 10 min). After washing with DMF (10 x 4 mL) the last coupling was accomplished by shaking the resin for 90 min with a solution of Boc-fl-Ala-OH
(85 mg, 0.44 mmol), HATU (0.17 g, 0.44 mmol), HOAt (0.9 ml, 0.5 M in DMF) and DIPEA (0.25 mL, 1.43 mmol) in DMF (1 mL). After washing with DMF (10 x 4 mL) and DCM (10 x 4 mL) the peptide was cleaved off the resin by treating with TFA/HFIP/TIPS/H20 (1:94:2.5:2.5, v/v/v/v, 2 x 5 mL, 2 x 40 min). The resulting solutions were combined and the volume was reduced to a total of 5 mL by a stream of N2. To the concentrated solution was added ice-cold diethyl ether. The formed suspension was centrifuged at 5000 x G at 0 C for ten minutes and the supernatant was discarded, The residue was dissolved in 5 mL ACN/H20/TFA
(1:1:0.002 v/v/v) and it was purified by RP-HPLC to give li as a colorless, glassy solid after lyophilization. Yield: 80 mg, 67 gmol (lx TFA 3 x TFA- salt), 30%. MS: m/z =
972.56 =
[M+2xTFA-] ', (calculated 972.56).
111 (32 mg, 46 mop was dissolved in DMF (1.14 mL) and li (47 mg, 53 mop was added.
To this mixture HATU (18 mg, 48 mop and DIPEA (67 L, 0.38 mmol) were added and it was stirred for 90 min. The reaction was quenched by addition of AcOH (67 L) and water was added to a total volume of 5 mL. The resulting solution was purified by RP-HPLC to give lj as colorless oil. Yield: 41 mg, 22 gmol (1 x TFA 3x TFA- salt), 48%. MS:
m/z = 769.97 =
[M-FTFA-]2 ', (calculated 769.89).

lj (41 mg, 22 mop was dissolved in TFA (1 mL) and stirred for 30 min before TFA was removed by a stream of N2. The residue was dissolved in H20/ACN/TFA 1:1:0.002 (1.5 mL), frozen and lyophilized to give the free acid as colorless oil containing additional amounts of 5 TFA. Yield: 63 mg, max. 22 gmol (3 x TFA- salt), quant. MS: m/z = 685.03 = [M-H]2', (calculated 684.86). To a solution of the free acid (21 mg, 12 Kmol) in DMF
(0.5 mL) was added Boc-l-tert-butoxy-1,2-dihydroisoquinoline (36 mg, 0.12 mmol). The mixture was stirred for 5 h before NHS (21 mg, 0.18 mmol) was added. The reaction was quenched by addition of AcOH (7 L) after 20 min. The mixture was cooled to 0 C and was afterwards 10 diluted with H20/ACN/TFA 1:1:0.002 to a total volume of 2.5 mL. This solution was purified by RP-HPLC to give lk as colorless oil. Yield: 11 mg, 5.2 gmol (1 x TFA 3 x TFA- salt), 43%. MS: m/z = 790.37 = [M-FTFA-]2', (calculated 790.37).
Example 2 15 Synthesis of purification tag 2e Purification tag 2e was synthesized according to the following scheme:
Boc,NH NH

Boc , H 1\1 L 1\15) H2N
NH N
n NH2 rN
60Co 0 2a 2b H N-Boo NH
H H
Boc_NH
Boc-NN'Boc O N 0 0 NyBoo HH N H
1\1).CI

I N
Boc-IN
r H
2c O
0,NH
Boo-NH
H N',NI-Boo Boo H

H 21\1NH 2 ICD'N 0 Oyw 2 NH
H H N
Q m N
BocN1 H
2d o NH
NrH 2 CD'NH 0 I 0 (:),N 00 I
H N
m I 0 H 0 1) 2e )\10NH (õNI

To a suspension of 6,6'-dithiodinicotinic acid (0.62 g, 2 mmol) in ACN (20 mL) were added PyBOP (2.08 g, 4 mmol) and DIPEA (1.29 g, 1.74 mL, 10 mmol) and the mixture was stirred for 1 min. The obtained brown solution was added to a solution of 1,9-bis-Boc-1,5,9-triazanonane (1.99 g, 6 mmol) in a mixture of ACN (20 mL) and DMF (5 mL) and stirred for 2 h. The reaction mixture was diluted with Et0Ac (150 mL) and the organic layer was washed with aq. HC1 (10 mM, 5 x 100 mL), saturated NaHCO3 solution (3 x 100 mL) and brine (100 mL), subsequently. After drying over MgSO4 and filtration, the solvent was removed in vacuo and the crude residue was purified by flash chromatography to give 2a (1.92 g, max. 2 mmol) as a light yellow foam. The product contains a small, non-separable amount of tripyrrolidine phosphoramide, which is removed in the next step. MS:
m/z = 935.47 = [M+H]', (calculated 935.47).
2a (1.92 g, max. 2 mmol) was dissolved in TFA (10 mL) and the solution was stirred for 10 min. The reaction mixture was added dropwise to ice-cold diethyl ether (160 mL) to precipitate the product. The resulting suspension was centrifuged at 7000 x G
and 2 C for 3 min. The supernatant was discarded and the precipitate was dissolved in methanol (10 mL).
This solution was added drop-wise to ice-cold diethyl ether (160 mL) and the formed suspension was centrifuged at 7000 x G and 2 C for 3 min. After discarding the supernatant the precipitation procedure was accomplished two more times like described above. The remaining oily precipitate was dried in vacuo to give 2b (1.77 g, 1.45 mmol (6 x TFA salt), 73%) as a light brown, very hygroscopic powder. MS: m/z = 535.26 = [M+H]', (calculated 535.26).
To a solution of 2b (3.30 g, 2.7 mmol) in DMF (90 mL) were added DIPEA (5.4 mL, 31 mmol) and Boc-L-Lys(Boc)-0Su (5.62 g, 12.7 mmol). The mixture was stirred for 14 h before it was diluted with ethyl acetate (600 mL). The organic layer was washed with aq. HC1 (10 mM, 5 x 300 mL), sat. NaHCO3 solution (3 x 300 mL) and brine (300 mL) and was dried over MgSO4. After filtration the solvent was removed in vacuo and the crude residue was purified by flash chromatography to give 2c (5.52 g, max. 2.7 mmol) as light yellow foam with 90 % purity. MS: m/z = 924.54 = [M+2H]2', (calculated 924.53).
2c (5.52 g, max. 2.7 mmol) was dissolved in TFA (20 mL). After stirring for 15 min the product was precipitated by adding the reaction mixture dropwise to ice-cold diethyl ether (160 mL). The resulting suspension was centrifuged at 7000 x G and 2 C for 3 min. The supernatant was discarded and the precipitate was dissolved in methanol (10 mL). This solution was added dropwise to ice-cold diethyl ether (160 mL) and the formed suspension was centrifuged at 7000 x G and 2 C for 3 min. After discarding the supernatant the precipitation procedure was accomplished two more times like described above.
The remaining oily precipitate was dried in vacuo to give 2d (4.96 g, 2.27 mmol (10 x TFA salt), 84%) as a light brown, hygroscopic powder. MS: m/z = 1046.64 = [M+H]', (calculated 1046.64).
To a solution of 2d (1.53 g, 0.7 mmol) in dry DMF (20 mL) was added a solution of N,N-diemethylglycine (1.16 g, 11.2 mmol), PyBOP (5.83 g, 11.2 mmol) and DIPEA
(3.23 g, 4.36 mL, 25 mmol) in DMF (35 mL) and stirred for 1 h. The mixture was then concentrated in vacuo to an approximate volume of 10 mL. To this residue water was added to a total volume of 100 mL and the solution was acidified to pH 1 ¨ 2 by adding TFA. The turbid mixture was centrifuged at 5000 x G and 2 C for 3 minutes. The oily precipitate was discarded and the supernatant was purified by RP-HPLC to give 2e (1.05 g, 0.37 mmol (10 x TFA
salt), 53%) as a colorless oil. MS: m/z = 864.54 = [M+2H]2', (calculated 864.54).
Example 3 Synthesis of linker reagent 3g Linker reagent 3g was synthesized according to the following scheme:
Trt S' T rt -2'.
I I
N,' 0 H Ni" N NBoc N,,,,NN H
'= =

3a 3b 3c OH OH OH
Trt s_ S H

-2- I N," = N N 0 _,.
'= NN0 H H

OH
3d 0 H 3e ------eo ------eo O\( H o ...H
S's _______________________________________________________________ NH /
N
Or 0 NN( / 0 I
N, ¨31. ...,... ,,.õ..õ/"...N----"\sõ,,N0 0 N¨

H o /
o o \N __ ) N
H
OH 3f -------e0 /

o H o /.....
S's H 7 H
N
O NN[ 1 /
o o I
N, ...,. ,,.õ...---...N....õ-N-.........--O 0 N¨

H o o , o ¨J.. % N
\/¨
N H
0 3g .....Z--2-Chlorotritylchloride resin (1.4 mmol/g, 1.43 g, 2 mmol) was weighted into a 20 ml syringe with fit. The resin was swollen twice with 10 mL DCM. N-Fmoc-N-methyl-L-Asp(OtBu)-OH (1.06 g, 2.5 mmol) was dissolved in DCM (6 mL) and drawn into the syringe.
DIPEA
(436 L, 2.5 mmol) was dissolved in DCM (1 mL) and drawn into the syringe. The syringe was agitated for 5 min. DIPEA (654 L, 3.75 mmol) was dissolved in DCM (1 mL) and drawn into the syringe. The syringe was agitated for 1 h. Me0H (2 mL) was drawn into the syringe and the syringe agitated for 30 min. The resin was washed 5 times with DMF (10 mL). The resin was agitated 3 times for 5 min with DMF:DBU:piperidine (96:2:2 v/v/v 7 mL). The resin was washed 5 times with DMF (5 mL). 6-Tritylmercaptohexanoic acid (1.95 g, 5 mmol) and PyBOP (2.6 g, 5 mmol) were dissolved in DMF (6 mL) and DIPEA
(3.5 mL, mmol) added. After 1 min preincubation the solution was drawn into the syringe and the syringe agitated for 3 h. The resin was washed 5 times with DMF (7 mL), 5 times with DCM
(7 mL). A solution of HFIP/DCM (1/4 v/v, 8 mL each) were drawn into the syringe and the syringe agitated 3 times for 30 min. The collected filtrates were concentrated in vacuo. Crude 3a (0.84 g, 1.45 mmol, 73 %) was used without further purification in the next step. MS: m/z 598.18= [M+Na]', (calculated = 598.26).

3a (1.67 g, 2.9 mmol) was dissolved in DCM (20 mL) and N-Boc-N-methylethylenediamine (0.62 mL, 3.48 mmol) and PyBOP (1.81 g, 3.48 mmol) were added. DIPEA (2.02 mL, 11.6 mmol) was added and the reaction stirred for 1 h. AcOH (2 mL) was added, the mixture 5 diluted with DCM (40 mL) and washed with water (2x20 mL). The organic layer was dried over MgSO4 and concentrated in vacuo and the crude residue was purified by flash chromatography to give 3b (1.74 g, 2.38 mmol, 82 %). MS: m/z = 754.19 =
[M+Na]', (calculated 754.39).
10 3b (1.74 g, 2.38 mmol) and triphenylmethanol (0.62 g, 2.38 mmol) were dissolved in DCM
(7.2 mL) and TFA (7.2 mL) was added with stirring. The reaction was stirred for 90 min and the solvents were removed in a stream of nitrogen over 45 min. The residue was co-evaporated with DCM. The residue was suspended in ACN/water/TFA (2:1:0.003 v/v/v, 14 mL) and filtered. The filtrate was purified by RP-HPLC to give 3c (0.9 g, 1.3 mmol TFA salt, 15 55 %). MS: m/z 576.20= [M+H]', (calculated = 576.29).
3c (0.9 g, 1.3 mmol) was dissolved in DCM (20 mL) and (5-methy1-2-oxo-1,3-dioxo1-4-y1)-methyl 4-nitrophenyl carbonate (0.46 g, 1.56 mmol) was added. DIPEA (0.45 mL, 2.6 mmol) was slowly added and the reaction stirred for 30 min. DIPEA (0.11 mL, 0.65 mmol) was 20 added and the reaction stirred for 30 min. Again, DIPEA (0.11 mL, 0.65 mmol) was added and the reaction stirred for 60 min. AcOH (0.68 mL) was added and the mixture concentrated in vacuo and the crude residue was purified by flash chromatography to give 3d (1.04 g, max.
1.3 mmol). MS: m/z = 754.28 = [M+Na]', (calculated 754.28).
25 3d (1.04 g, max. 1.3 mmol) was dissolved in HFIP/TES/water (39:1:1 v/v/v, 8.2 mL) and TFA (0.66 mL) was added. After stirring for 15 min the reaction was concentrated in vacuo, the residue suspended in ACN/water/TFA (1:1:0.002 v/v/v 12 mL) and filtered.
The filtrate was purified by RP-HPLC to give 3e (0.32 g, 0.65 mmol, 50 %). MS: m/z 490.19=
[M+H]', (calculated = 490.19).
3e (0.18 g, 0.37 mmol) was dissolved in ACN/water/TFA (1:1:0.002 v/v/v, 3 mL).
2e (1.05 g, 0.37 mmol (10 x TFA salt) was dissolved in ACN/water (1:1 v/v, 20 mL). Both solutions were combined and pH 7.4 sodium phosphate (0.5 M, 4 mL) was added and the mixture stirred for 30 min. The pH of the solution was adjusted to ca. pH 2 by addition of ACN/water/TFA (1:1:0.22 v/v/v) and ACN was removed in vacuo. The residue was purified by RP-HPLC to give 3f (0.47 g, 0.24 mmol 5xTFA salt, 65 %). MS: m/z 676.86=
[M+2H]2', (calculated = 676.86).
3f (0.18 g, 94 mop was dissolved in ACN (6 mL) and NHS (92 mg, 0.8 mmol) and DCC
(166 mg, 0.8 mmol) were added and the reaction stirred for lh. The solvent was removed in vacuo and the residue suspended in ACN/water/TFA (0.15:0.85:0.001 v/v/v, 6 mL) and filtered. The filtrate was purified by RP-HPLC to give 3g (129 mg, 64 gmol 5xTFA salt, 68 %). MS: m/z 725.37= [M+H] ', (calculated = 725.37).
Example 4 Synthesis and purification of transient tagged Lucentis-linker-monoconjugate 4b 120 mg Lucentis (depicted in the scheme below as Lucentis-NH2) (3 mL of 40 mg/mL
Lucentis in 10 mM histidine, lOwt% a,a-trehalose, 0.01% Tween20, pH 5.5) was buffer exchanged to 60 mM sodium phosphate, 100 mM sodium chloride, pH 7.4 and the concentration of Lucentis was adjusted to 19 mg/mL. Linker reagent lk was dissolved in DMSO to yield a concentration of 50 mM. 4 molar equivalents of linker reagent lk relative to the amount of Lucentis were added to the Lucentis solution in 1 molar equivalent steps. The reaction mixture was mixed carefully after each linker reagent addition and incubated for 5 min at room temperature yielding a mixture of unmodified Lucentis, the protected, tagged Lucentis-linker monoconjugate 4a as well as protected, tagged Lucentis-linker bisconjugate.
The mixture of unmodified Lucentis, protected, tagged Lucentis-linker monoconjugate 4a and protected, tagged Lucentis-linker bisconjugate was buffer exchanged to 20 mM
boric acid, pH
9.0 and incubated for 2 h at room temperature to remove the (5-methy1-2-oxo-1,3-dioxol-y1)-methyl oxocarbonyl protecting group of 4a yielding the tagged Lucentis-linker monoconjugate 4b.
4b was purified from the reaction mixture by cationic ion exchange chromatography using an Aekta Purifier system equipped with a Source 15S 4.6/100 column. After loading of the reaction mixture (5-fold prediluted in mobile phase A) the following gradient of mobile phase A (20 mM MES, pH 5.7) and mobile phase B (20 mM MES, 500 mM NaC1, pH 5.7) was applied: linear increase from 3.2% B to 50% B in 20 column volumes leading to a separation of 4b from Lucentis and tagged Lucentis-linker bisconjugate (Fig. 1).

\ .
---N+
00 %
_...f E..<00 \ /
---N+
N
H \--:\----)4 N
0 L\ lk H2 c<L)-N

N
0....)\--H

0......0 .....7--0 o 0 aqueous buffer + Lucentis-NH2 pH 7.4 v 'I
---N.
0 4a HN-Lucentis \ /
----N.
N
H
N
0 \.......\

0---)\----HN 0 c----/
S N:¨._ N ,\

----G--\( N

4a aqueous buffer pH 9.0 V
'I
---N.

......_f.......17(1 0 HN-Lucentis N
4b \ /
N ---.
H
\---0\--).......\<NH 2 N

\---\ \---c-----).....iNH.
___)---11 0 N :
H-A......\Th...... 0--)\----NH 0 or--j H
N
N---/-----SµsN -----0--i 0 N

Example 5 Deprotection of transient tagged Lucentis-linker-monoconjugate 4b yielding Lucentis-linker monoconjugate 5a Purified transient tagged Lucentis-linker-monoconjugate 4b was buffer exchanged to 15 mM
succinic acid, 100 mM sodium chloride, 5 mM Na2EDTA, pH 4.0 and the protein concentration was adjusted to 1 mg/mL. The protein solution was cooled to 4 C
and 2 molar equivalents of 25 mM DTT in 15 mM succinic acid, 100 mM sodium chloride, 5 mM
Na2EDTA, pH 4.0 were added and incubated overnight at 4 C yielding the Lucentis-linker monoconjugate 5a.
4b aqueous buffer 2 eq. DTT
pH 4, 4 C

---- 0( -- HN-Lucentis N
H ----I- h--",0 N 5a 0 \........\
N
H-----\........\......\.....
SH
Example 6 Synthesis and purification of transient tagged Lucentis-linker monoconjugate 6b 400 mg Lucentis (depicted in the scheme below as Lucentis-NH2) (10 mL of 40 mg/mL
Lucentis in 10 mM histidine, lOwt% a,a-trehalose, 0.01% Tween20, pH 5.5) was buffer buffer exchanged to 60 mM sodium phosphate, 100 mM sodium chloride, pH 7.4 and the concentration of Lucentis was adjusted to 20.8 mg/mL. Linker reagent 3g was dissolved in DMSO to yield a concentration of 100 mM. 4.5 molar equivalents of linker reagent 3g relative to the amount of Lucentis were added to the Lucentis solution. The reaction mixture was mixed carefully and incubated for 5 min at room temperature yielding a mixture of unmodified Lucentis, the protected, tagged Lucentis-linker monoconjugate 6a and protected, tagged Lucentis-linker bisconjugate.
The mixture of Lucentis, protected, tagged Lucentis-linker monoconjugate 6a and protected, tagged Lucentis-linker bisconjugate was buffer exchanged to 60 mM sodium phosphate, 100 mM sodium chloride, pH 6.5. To remove the (5-methyl-2-oxo-1,3-dioxol-y1)-methyl oxocarbonyl protecting group of 6a 0.5 M NH2OH (dissolved in 10 mM sodium citrate, 140 mM sodium chloride, 5 mM Na2EDTA, pH 6.5) was added to a final concentration of 45 mM
and the deprotection reaction was incubated at room temperature for 2.5 h yielding the tagged Lucentis-linker monoconjugate 6b.
6b was purified from the reaction mixture by cationic ion exchange chromatography using an Aekta Purifier system equipped with a Source 15S 6 mLcolumn (Fig. 2). After loading of the reaction mixture (5-fold prediluted in mobile phase A) the following gradient of mobile phase A (20 mM MES, pH 5.7) and mobile phase B (20 mM MES, 500 mM NaC1, pH 5.7) was applied: linear increase from 0% B to 50% B in 20 column volumes leading to a separation of 6b from Lucentis and tagged Lucentis-linker bisconjugate.

N/
Oy HN N
=,..., Oy N
t,õ,,.N H 0 0 y , H N' 0 HN\I H
(Nõc) N
0 j---... Ni 0 Ri HNõ 0 NN)rN S
N/
.--).----00 0 1 0 3g I
),.....¨o aqueous buffer pH 7.4 + Lucentis-NH2 Y
N
Oy HN N/
/4,...N H 0 Lucentis-NH
..--"--- N
Ni 0 Ri HN, 0 NN)rN S
6a .-`).-=:<.-'-00 0 j.....1 0 \ N/

I
>_.-0 6a aqueous buffer H 6.5 + 45 mM NH2OH
p V
\ N/
0y HN N/
0y0 , ),..c Lucentis-NH
,-, Ni 0 K
H I
0 0 S 6b N/
I
Example 7 Deprotection of transient tagged Lucentis-linker-monoconjugate 6b yielding Lucentis-linker monoconjugate 7a Purified transient tagged Lucentis-linker-monoconjugate 6b was buffer exchanged to 15 mM
succinic acid, 100 mM sodium chloride, 5 mM Na2EDTA, pH 4.0 and the protein concentration was adjusted to 10 mg/mL. The protein solution was cooled to 4 C
and 5 molar equivalents of 25 mM DTT in 15 mM succinic acid, 100 mM sodium chloride, 5 mM
Na2EDTA, pH 4.0 were added and incubated overnight at 4 C yielding the Lucentis-linker monoconjugate 7a.

6b aqueous buffer pH 4, 4 C + 5 eq DTT
If Lucentis-NH
Pil NN)-rN
H

Abbreviations:
ACN acetonitrile AcOH acetic acid Ado 8-amino-3,6-dioxaoctanoic acid aq. aqueous Asp aspartate I3-Ala beta-alanine Boc tert-butyloxycarbonyl CIEC cationic ion exchange chromatography cv column volume DBU 1,8-diazabicyclo (5.4.0)undec-7-ene DCC dicyclohexylcarbodiimide DCM dichloromethane DIPEA diisopropylethylamine DMF dimethylformamide DTT dithiothreitol EDTA ethylendiaminetetraacetic acid Fmoc fluorenylmethyloxycarbonyl HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate HFIP hexafluoroisopropanol HOAt 1-hydroxy-7-azabenzotriazo le HOBt 1-hydroxybenzotriazo le HPLC high performance liquid chromatography Lys lysine max. maximal Me methyl Me0H methanol MES 2-(N-morpholino)ethanesulfonic acid MS mass spectrometry NHS N-hydroxysuccinimide PyBOP benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate RP-HPLC reversed phase ¨ high performance liquid chromatography sat. saturated Su N-hydroxusuccinimidyl tBu and t-Bu tert.-butyl TES triethylsilane TFA trifluoroacetic acid THF tetrahydrofurane TLC thin layer chromatography Trt trityl TBTU N,N,N'N'-tetramethy1-0-(benzotriazol-1-y1)uronium tetrafluoroborate

Claims (22)

Claims
1. A compound comprising a moiety of formula (I) T ¨ PG ~ (I), wherein the dashed line indicates attachment to the rest of the compound;
T is a tag moiety; and PG is a protecting group moiety.
2. The compound of claim 1, wherein PG is used for the reversible protection of an amine functional group and wherein PG comprises a moiety of formula (Aa), (Ab) or (Ac):
wherein the dashed line marked with the asterisk indicates attachment to T and the unmarked dashed line indicates attachment to the nitrogen of an amine functional group;
n is 0, 1, 2, 3, or 4;

-X- is a chemical bond or a spacer;
=Y1 is selected from the group consisting of =O and =S;
-Y2- is selected from the group consisting of -O- and -S-;
-Y3-, -Y5- are independently of each other selected from the group consisting of -O-and -S-;
-Y4- is selected from the group consisting of -O-, -NR5- and -C(R6R6a)-;
-R2, -R3, -R4, -R5, -R6, -R6a are independently of each other selected from the group consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl;
-W- is selected from the group consisting of C1-20 alkyl optionally interrupted by one or more groups selected from the group consisting of -O-, -S- and -N(R7)-;
-Nu is a nucleophile selected from the group consisting of -N(R7R7a), -N(R7OH), -N(R7)-N(R7a R7b), -S(R7),-COOH, -Nu' is a nucleophile selected from the group consisting of -N(R7)-, -N(OH)-, -N(R7)-N(R7a)-, -S-,-C(O)O-, wherein the unmarked dashed line indicates attachment to the rest of the moiety of formula (Ac) and the dashed line marked with the asterisk indicates attachment to T
-Ar- is selected from the group consisting of wherein dashed lines indicate attachment to the rest of the prodrug, -Z1- is selected from the group consisting of -O-, -S- and -N(R7)-, and -Z2- is -N(R7)-; and -R7, -R7a, -R7b are independently of each other selected from the group consisting of -H, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl;
wherein the moiety of formula (Aa), (Ab) and (Ac) is optionally further substituted.
3. The compound of claim 1, wherein PG is used for the reversible protection of an amine functional group and wherein PG of formula (I) preferably comprises a moiety of formula (C):
wherein the dashed line marked with the asterisk indicates attachment to T of formula (I) and the unmarked dashed line indicates attachment to the nitrogen of an amine functional group;
X is C(R4R4a); N(R4); O; C(R4R4a)-C(R5R5a); C(R5R5a)-C(R4R4a);
C(R4R4a)-N(R6); N(R6)-C(R4R4a); C(R4R4a)4a)-O; or O-C(R4R4a);
X1 is C; or S(O);
X2 is C(R7, R7a); or C(R7, R7a)-C(R8, R8a);
R1, R1a, R2, R2a, R3, R3a, R4, R4a, R5, R5a, R6, R7, R7a, R8, R8a are independently selected from the group consisting of H; and C1-4 alkyl;
optionally, one or more of the pair(s) R1a/R4a, R1a/R5a, R4a/R5a, R4a/R5a, R7a/R8a form a chemical bond;
optionally, one or more of the pair(s) R1/R1a, R2/R2a, R4/R4a, R5/R5a, R7/R7a, R8/R8a are joined together with the atom to which they are attached to form a C3-8 cycloalkyl; or 4- to 7-membered heterocyclyl;
optionally, one or more of the pair(s) R1/R4, R1/R5, R1/R6, R4/R5, R7/R8, R2-R3 are joined together with the atoms to which they are attached to form a ring A;
optionally, R3/R3a are joined together with the nitrogen atom to which they are attached to form a 4- to 7-membered heterocycle;

A is selected from the group consisting of phenyl; naphthyl;
indenyl; indanyl;
tetralinyl; C3-10 cycloalkyl; 4- to 7-membered heterocyclyl; and 8- to 11-membered heterobicyclyl;
provided that one hydrogen of R1, R1a, R2, R2a, R3, R3a, R4, R4a, R5, R5a, R6, R7, R7a, R8 or R8a is replaced by ¨T of formula (I); and wherein the moiety of formula (C) is optionally further substituted.
4. The compound of claim 15 wherein PG is used for the reversible protection of a thiol functional group and PG is selected from the group consisting of wherein the dashed line marked with an asterisk indicates attachment to T and the unmarked dashed line indicates attachment to the rest of the compound;
Ar is an aromatic moiety which is optionally further substituted; and R01, R03, R04 are independently of each other a chemical bond or is C1-50 alkyl; C2-50 alkenyl; or C2-50 alkynyl, wherein C1-50 alkyl; C2-50 alkenyl; and C2-50 alkynyl are optionally substituted with one or more R3, which are the same or different and wherein C1-50 alkyl; C2-50 alkenyl; and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -Q-, -C(O)O-; -O-; -C(O)-; -C(O)N(R4)-;
-S(O)2N(R4)-; -S(O)N(R4)-; -S(O)2-; -S(O)-; -N(R4)S(O)2N(R4a)-; -S-;
-N(R4)-; -OC(O)R4; -N(R4)C(O)-; -N(R4)S(O)2-; -N(R4)S(O)-;
-N(R4)C(O)O-; -N(R4)C(O)N(R4a)-; and -OC(O)N(R4R4a);
R02 is -H; C1-50 alkyl; C2-50 alkenyl; or C2-50 alkynyl, wherein C1-50 alkyl;

50 alkenyl; and C2-50 alkynyl are optionally substituted with one or more R3, which are the same or different and wherein C1-50 alkyl; C2-50 alkenyl; and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -Q-, -C(O)O-; -O-; -C(O)-;
-C(O)N(R4)-; -S(O)2N(R4)-; -S(O)N(R4)-;
-S(O)2-; -S(O)-;
-N(R4)S(O)2N(R4a)-; -S-; -N(R4)-; -OC(O)R4; -N(R4)C(O)-;
-N(R4)S(O)2-; -N(R4)S(O)-; -N(R4)C(O)O-; -N(R4)C(O)N(R4a)-; and -OC(O)N(R4R4a);
Q is selected from the group consisting of phenyl; naphthyl; indenyl;
indanyl; tetralinyl; C3-10 cycloalkyl; 4- to 7-membered heterocyclyl; and 8- to 11- membered heterobicyclyl, wherein T is optionally substituted with one or more R3, which are the same or different;
R3 is halogen; -CN; oxo (=O); -COOR5; -OR5; -C(O)R5; -C(O)N(R5R5a);
-S(O)2N(R5R5a); -S(O)N(R5R5a); -S(O)2R5; -S(O)R5;
-N(R5)S(O)2N(R5a R5b); -SR5; -N(R5R5a); -NO2; -OC(O)R5;
-N(R5)C(O)R5a; -N(R5)S(O)2R5a; -N(R5)S(O)R5a; -N(R5)C(O)OR5a;
-N(R5)C(O)N(R5a R5b); -OC(O)N(R5R5a); or C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; and R4, R4a, R5, R5a, R5b are independently selected from the group consisting of -H; or C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different.
5. The compound of claim 4, wherein Ar is selected from the group consisting of wherein dashed lines marked with an asterisk indicate attachment to T of formula (I) and the unmarked dashed lines indicate attachment to the rest of PG;
W is independently of each other O, S, or N;
W' is N; and wherein Ar is optionally substituted with one or more substituent(s) independently selected from the group consisting of NO2, Cl and F.
6. The compound of claims 4 or 5, wherein PG is wherein the dashed line marked with an asterisk indicates attachment to T and the unmarked dashed line indicates attachment to the rest of the compound.
7. The compound of any one of claims 1 to 6, wherein T comprises at least one positive or negative charge.
8. The compound of any one of claims 1 to 7, wherein T comprises at least one positive charge under aqueous conditions at pH 3 to 9.
9. The compound of claim 8, wherein the at least one positive charge is provided by an ammonium, phosphonium or tertiary amine.
10. The compound of any one of claims 1 to 9, wherein T comprises a polyamide comprising at least one tertiary amine, quaternary ammonium residue and/or at least one protonated ammonium residue, optionally comprising further functional groups
11. The compound of any one of claims 1 to 10, wherein T comprises a moiety of formula (a):
wherein the dashed line indicates attachment to the rest of the compound;
R1, R1a, R1b, R2, R2a, R2b, R3, R3a, R3b, R4, R4a, R4b are independently of each other H
or methyl;
each m is independently of each other 1, 2, 3, 4, 5, 6, 7, or 8;

each n is independently of each other 1, 2, 3, 4, 5, 6, 7, or 8;
each x is independently of each other 1, 2, 3, 4, 5, 6, 7 or 8:
each y is independently of each other 0, 1, 2, 3, 4, 5, 6, 7 or 8; and SP is a spacer moiety.
12. The compound of any one of claims 1 to 10, wherein T comprises a moiety of formula (b):
wherein the dashed line indicates attachment to PG of formula (I);
q is 0 or 1; and SP is a spacer moiety.
13. The compound of any one of claims 1 to 12, wherein the compound comprises a moiety of formula compound comprising a moiety of formula (IIa) T ¨ PG ¨ L2¨ L1- (IIa), wherein the dashed line indicates attachment to the rest of the compound;
T and PG are used as defined in formula (I);
L2 is a chemical bond or a spacer moiety;
L1 reversible prodrug linker moiety.
14. The compound of claim 13, wherein L2 is a spacer moiety.
15. The compound of claim 13 or 14, wherein L2 is of formula (IIa) is selected from -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R y1)-, -S(O)2N(R y1)-, -S(O)N(R y1)-, -S(O)2-, -S(O)-, -N(R y1)S(O)2N(R y1a)-, -S-, -N(R y1)-, -OC(OR y1)(R y1a)-, -N(R y1)C(O)N(R
y1a)-, -OC(O)N(R y1)-, C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein -T-, C1-20 alkyl, C2-20 alkenyl, and C2-20 alkynyl are optionally substituted with one or more R
y2, which are the same or different and wherein C1-20 alkyl, C2-20 alkenyl, and C2-20 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R y3)-, -S(O)2N(R y3)-, -S(O)N(R y3)-, -S(O)2-, -S(O)-, -N(R y3)S(O)2N(R y3a)-, -S-, -N(R y3)-, -OC(OR y3)(R y3a)-, -N(R y3)C(O)N(R
y3a)-, and -OC(O)N(R y3)-;
R y1 and R y1a are independently of each other selected from the group consisting of -H, -T, C1-10 alkyl, C2-10 alkenyl, and C2-10 alkynyl; wherein -T, C1-10 alkyl, C2-10 alkenyl, and C2-10 alkynyl are optionally substituted with one or more R y2, which are the same or different, and wherein C1-10 alkyl, C2-10 alkenyl, and C2-10 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R y4)-, -S(O)2N(R y4)-, -S(O)N(R y4)-, -S(O)2-, -S(O)-, -N(R y4)S(O)2N(R y4a)-, -S-, -N(R y4)-, -OC(OR y4)(R y4a)-, -N(R y4)C(O)N(R
y4a)-, and each T is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; wherein each T is independently optionally substituted with one or more R y2, which are the same or different;
R y2 is selected from the group consisting of halogen, -CN, oxo (=O), -COOR
y5, -OR y5, -C(O)R y5, -C(O)N(R y5R y5a), -S(O)2N(R y5R y5a), -S(O)N(R y5R y5a), -S(O)2R
y5, -S(O)R y5, -N(R y5)S(O)2N(R y5a R y5b), -SR y5, -N(R y5R y5a), -NO2, -OC(C)R y5, -N(R
y5)C(O)R y5a, -N(R y5)S(O)2R y5a, -N(R y5)S(C)R y5a, -N(R y5)C(O)OR y5a, -N(R y5)C(O)N(R y5a R y5b), -OC(C)N(R y5R y5a), and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; and each R y3, R y3a, R y4, R y4a, R y5, R y5a and R y5b is independently of each other selected from the group consisting of -H, and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different.
16. The compound of any one of claims 13 to 15, wherein L1 comprises a moiety of formula (b-iii) wherein the dashed line with marked with the asterisk indicates attachment to L2 of formula (IIa) and the unmarked dashed line indicates attachment to the rest of the compound comprising the moiety of formula (IIa), which moiety of formula (b-iii) is attached to the rest of the compound through an amine functional group provided by said rest of the compound by forming an amide linkage between L1 and the rest of the compound comprising the moiety of formula (IIa);
X of formula (b-iii) is C(R4R4a); N(R4); O; C(R4R4a)-C(R5R5a); C(R5R5a)-C(R4R4a);
C(R4R4a)-N(R6); N(R6)-C(R4R4a); C(R4R4a)-O; or O-C(R4R4a);
X1 of formula (b-iii) is C; or S(O);
X2 of formula (b-iii) is C(R7, R7a); or C(R7, R7a)-C(R8, R8a);
X3 of formula (b-iii) is O; S; or N-CN;
R1, R1a, R2, R2a, R3, R3a, R4, R4a, R5, R5a, R6, R7, R7a, R8, R8a of formula (b-iii) are independent of each other selected from the group consisting of H; and C1-4 alkyl;
optionally, one or more of the pairs R1a/R4a, R1a/R5a, R4a/R5a, R7a/R8a of formula (b-iii) form a chemical bond;
optionally, one or more of the pairs R1/R1a, R2/R2a, R4/R4a, R5/R5a,R7/R7a, R8/R8a of formula (b-iii) are joined together with the atom to which they are attached to form a C3-10 cycloalkyl; or 4- to 7-membered heterocyclyl;

optionally, one or more of the pairs R1/R4, R1/R5, R1/R6, R4/R5, R4/R6, R7/R8, R2/R3 of formula (b-iii) are joined together with the atoms to which they are attached to form a ring A;
optionally, R3/R3a of formula (b-iii) are joined together with the nitrogen atom to which they are attached to form a 4- to 7-membered heterocycle;
A of formula (b-iii) is selected from the group consisting of phenyl;
naphthyl; indenyl;
indanyl; tetralinyl; C3-10 cycloalkyl; 4- to 7-membered heterocyclyl; and 8-to 11-membered heterobicyclyl; and wherein the moiety of formula (b-iii) is substituted with L2 of formula (IIa) and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (b-iii) is not replaced and that R3 and R3' of formula (b-iii) are independently of each other H or are connected to N through an SP3-hybridized carbon atom.
17. The compound of any one of claims 1 to 16, wherein the compound is of formula (IIIa) (T ¨ PG ¨ L2- L1 ~PM (IIIa), wherein T and PG are used as defined in formula (I);
L1 and L2 are used as defined in formula (IIa);
x is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20; and PM is a moiety having a molecular weight of at least 1 kDa.
18. The conjugate of claim 17, wherein PM is a protein.
19. The conjugate of claim 17 or 18, wherein PM comprises and antibody or antibody fragment.
20. A method of purification, comprising the steps of (i) Providing a mixture comprising a multitude of conjugates of formula (III) or (IIIa) of any one of claims 13 to 19 which differ by their value for x;

(ii) Subjecting the mixture of step (i) to a purification method suitable for the tag moiety T; and (iii) Isolating a fraction that comprises compounds of formula (III) or (IIIa) in which at least 80% of all compounds of formula (III) or (IIIa) have the same value for x.
21. The method of claim 20, wherein T comprises a charged moiety and the purification method of step (ii) is ion exchange chromatography.
22. A monoconjugate obtainable from the method of claim 20 or 21, in which x in step (iii) is 1.
CA2925190A 2013-10-08 2014-10-07 Protecting group comprising a purification tag Active CA2925190C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13187768.0 2013-10-08
EP13187768 2013-10-08
PCT/EP2014/071386 WO2015052155A1 (en) 2013-10-08 2014-10-07 Protecting group comprising a purification tag

Publications (2)

Publication Number Publication Date
CA2925190A1 true CA2925190A1 (en) 2015-04-16
CA2925190C CA2925190C (en) 2021-10-12

Family

ID=49447929

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2925190A Active CA2925190C (en) 2013-10-08 2014-10-07 Protecting group comprising a purification tag

Country Status (5)

Country Link
US (2) US10040850B2 (en)
EP (1) EP3054981B1 (en)
AU (1) AU2014333954C1 (en)
CA (1) CA2925190C (en)
WO (1) WO2015052155A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6946182B2 (en) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ Therapeutic Vitamin D Conjugate
SMT202400423T1 (en) 2016-03-01 2024-11-15 Ascendis Pharma Bone Diseases As Pth prodrugs
PT3518982T (en) 2016-09-29 2025-01-29 Ascendis Pharma Bone Diseases As Incremental dose finding in controlled-release pth compounds
RS64440B1 (en) 2016-09-29 2023-09-29 Ascendis Pharma Bone Diseases As Dosage regimen for a controlled-release pth compound
NZ792622A (en) * 2016-09-29 2025-08-29 Ascendis Pharma Bone Diseases As Pth compounds with low peak-to-trough ratios
AU2018240375C1 (en) 2017-03-22 2024-02-01 Ascendis Pharma A/S Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
EP3923905A1 (en) 2019-02-11 2021-12-22 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of pth conjugates
JP2025534350A (en) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド Long-acting parathyroid hormone
TW202430223A (en) 2023-01-05 2024-08-01 丹麥商阿仙帝斯眼科製藥有限公司 Drug conjugates for the treatment of ocular disorders
TW202434299A (en) 2023-01-05 2024-09-01 丹麥商阿仙帝斯製藥公司 Methods of producing hydrogel microspheres

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495125B2 (en) 1999-01-08 2002-12-17 The Procter & Gamble Company Topical compositions comprising protected functional thiols
WO2000075162A1 (en) 1999-06-07 2000-12-14 Mirus Corporation A compound containing a labile disulfide bond
WO2002043663A2 (en) * 2000-12-01 2002-06-06 Enzon, Inc. Tetrapartate prodrugs
DE10329860A1 (en) 2003-07-02 2005-01-20 Atto-Tec Gmbh Sulfonamide derivatives of polycyclic dyes for analytical applications
EP2087910B1 (en) 2004-03-23 2022-05-04 Ascendis Pharma GmbH Polymeric prodrugs
US20060178507A1 (en) * 2004-12-30 2006-08-10 Berry & Associates, Inc. Fluorous oligonucleotide reagents and affinity purification of oligonucleotides
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
DE102005054700B4 (en) * 2005-11-16 2009-01-08 Imtm Gmbh New dual peptidase inhibitors as prodrugs for the treatment of inflammatory and other diseases
RU2010136023A (en) 2008-02-01 2012-03-10 Асцендис Фарма Ас (Dk) A MEDICINE CONTAINING A SELF-DIVISIBLE LINKER
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
WO2011042450A1 (en) * 2009-10-06 2011-04-14 Ascendis Pharma As Carrier linked paliperidone prodrugs
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
US20130030359A1 (en) 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
EP2525830B1 (en) 2010-01-22 2016-05-11 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
WO2012149335A2 (en) 2011-04-28 2012-11-01 Richard Neubig Small molecule inhibitors of rgs proteins
CA2843506C (en) 2011-08-12 2020-05-12 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
ES2959385T3 (en) * 2012-10-11 2024-02-26 Ascendis Pharma Ophthalmology Div A/S VEGF-neutralizing prodrugs comprising ranibizumab for the treatment of ocular conditions characterized by ocular neovascularization

Also Published As

Publication number Publication date
WO2015052155A1 (en) 2015-04-16
AU2014333954B2 (en) 2020-03-05
EP3054981B1 (en) 2020-07-29
AU2014333954A1 (en) 2016-04-07
CA2925190C (en) 2021-10-12
US20180312582A1 (en) 2018-11-01
US10040850B2 (en) 2018-08-07
AU2014333954C1 (en) 2020-08-27
US20160257739A1 (en) 2016-09-08
EP3054981A1 (en) 2016-08-17

Similar Documents

Publication Publication Date Title
CA2925190A1 (en) Protecting group comprising a purification tag
ES2733355T3 (en) Prodrug comprising a self-cleavable linker
US11141489B2 (en) Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid
ES2390816T3 (en) N, N-bis- (2-hydroxyethyl) glycine amide as a linker in polymer conjugated prodrugs
CA2753001A1 (en) Interferon alpha carrier prodrugs
ES2759752T3 (en) Prodrugs comprising a GLP-1 / Glucagon dual agonist linker and hyaluronic acid conjugate
BR112019021810A2 (en) PROLONGED RELEASE SYSTEMS THAT UNDERSTAND NON-VESTIGINAL BINDERS
JP6539729B2 (en) Peptide-drug complex
WO2011089215A1 (en) Dipeptide-based prodrug linkers for aromatic amine-containing drugs
AU2013328785A1 (en) Hydrogel prodrugs
CA2911478A1 (en) Conjugates for protection against nephrotoxic active compounds
AU2014345511A1 (en) Relaxin prodrugs
US20230131339A1 (en) Epi-x4 based peptides and derivatives thereof
US9447149B2 (en) Methods and compositions for the rapid synthesis of radiometal-labeled probes
KR20240150763A (en) Compounds, compositions, and methods of use comprising raltitrexide or 5-MTHF linked to a therapeutic agent
HK1227750B (en) Protecting group comprising a purification tag
HK1227750A1 (en) Protecting group comprising a purification tag
US20220304993A1 (en) Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
Diez-Torrubia et al. Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs
RU2798085C9 (en) Prodrug containing a self-cleavable linker
RU2798085C2 (en) Prodrug containing a self-cleavable linker
CN120617534A (en) Three-fork-shaped small molecule drug conjugate and preparation method thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190809